| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA Date example | MR-100A-01 (investigational low-dose estrogen CHC weekly patch) Contraception; women of childbearing potential | PDUFA | — | Subscribe to access the data. | Hormone Therapies | Endocrine System | |
PDUFA Date example | MR-100A-01 (investigational low-dose estrogen CHC weekly patch) Contraception; women of childbearing potential | PDUFA | — | Subscribe to access the data. | Hormone Therapies | Endocrine System | |
PDUFA Date example | MR-100A-01 (investigational low-dose estrogen CHC weekly patch) Contraception; women of childbearing potential | PDUFA | — | Subscribe to access the data. | Hormone Therapies | Endocrine System |
Recent Updates
Recently added Catalysts
Viatris Inc.$17.33
+0.57 (+3.42%)
A 90Pipeline Score Undervalued Generics · Commercial
Market Cap
19.39 B
EPS
-0.26
P/E Ratio
-
Value Trade
108.54 M
SEC Financials
Q1 2026Dilution Risk
Revenue
3.52 B
R&D Expenses
248.60 M
Operating CF
388.30 M
Total Assets
36.83 B
Total Liabilities
22.18 B
Equity
14.66 B
D/E Ratio
12,345
-3 %
Week
12.42 %
1 Month
4.39 %
3 Month
62.44 %
6 Month
7.42 %
5 Year
33,200 %
All Time
Cash Data
Cash Position
1.81 B
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 7, 2026
Overview
Volume
9.48 M
52 Week Range
8.32 - 17.53
% held by Insiders
2.04 %
% held by Institutions
86.26 %
Enterprise Value
31.74 B
Total Shares
1.16 B
Short %
4.18 %
Float Shares
1.16 B
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Viatris Inc.
316Total events
9Upcoming
116Tier-1 (high impact)
2020 – 2027Coverage
Upcoming catalysts 2
TBD
T1PDUFA Date
Subscribe to view catalyst details
TBD
T1PDUFA Date
Subscribe to view catalyst details
Event history 2
TBD
▲Topline ReadoutVR-205FiledClinical Data
Subscribe to view catalyst details
TBD
▲Primary Endpoint MetVR-205FiledClinical Data
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2024-12-23 | Arixtra (fondaparinux sodium) | PDUFA Date | PDUFA | Approved | – | – | – |
2024-12-23 | Arixtra (fondaparinux sodium) | PDUFA Date | PDUFA | Approved | – | – | – |
2024-12-23 | Arixtra (fondaparinux sodium) | PDUFA Date | PDUFA | Approved | – | – | – |
Drug Pipeline Intelligence
A90
Pipeline Score $74.4B
Pipeline ValueUndervalued
Valuation Signal103
Drugs Scored12.8x
rNPV / MCap Top 99%
Mid Cap (rank 10 of 912)
Percentile RankViatris Inc. earns an A-grade pipeline score (90/100), with $87.5B risk-adjusted pipeline value, led by MYL-1501D product using manufacture process V in Diabetes Mellitus, Type 1 (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MYL-1501D product using manufacture process V Small molecule | Diabetes Mellitus, Type 1 | Phase 3 | NCT03376789 | 58% | $15.0B | COMPLETED | 219 | - | - | Jan 10, 2019 | - | Mar 3, 2022 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
VR-205 | primary immunoglobulin A nephropathy | Phase 3 | 2026-06-29 | 33.75 percent reduction in geometric mean urine protein-to-creatinine ratio at 9 months compared to baseline; statistically significant and clinically meaningful reduction in UPCR at 6 and 12 months; significant improvement in estimated glomerular filtration rate; reductions in serum creatinine and urine albumin-to-creatinine ratio at 9 months; no study participants progressed to dialysis, kidney transplant or severe renal impairment Read More | Viatris Announces Positive Top-Line Results from Phase 3 Study of VR-205 in Japanese Adults with Primary Immunoglobulin A Nephropathy Read More | |
VR-205 | primary immunoglobulin A nephropathy | Phase 3 | 2026-06-29 | 33.75 percent reduction in geometric mean urine protein-to-creatinine ratio at 9 months compared to baseline; statistically significant and clinically meaningful reduction in UPCR at 6 and 12 months; significant improvement in estimated glomerular filtration rate; reductions in serum creatinine and urine albumin-to-creatinine ratio at 9 months; no study participants progressed to dialysis, kidney transplant or severe renal impairment Read More | Viatris Announces Positive Top-Line Results from Phase 3 Study of VR-205 in Japanese Adults with Primary Immunoglobulin A Nephropathy Read More | |
VR-205 | primary immunoglobulin A nephropathy | Phase 3 | 2026-06-29 | 33.75 percent reduction in geometric mean urine protein-to-creatinine ratio at 9 months compared to baseline; statistically significant and clinically meaningful reduction in UPCR at 6 and 12 months; significant improvement in estimated glomerular filtration rate; reductions in serum creatinine and urine albumin-to-creatinine ratio at 9 months; no study participants progressed to dialysis, kidney transplant or severe renal impairment Read More | Viatris Announces Positive Top-Line Results from Phase 3 Study of VR-205 in Japanese Adults with Primary Immunoglobulin A Nephropathy Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in VTRS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
VTRS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
VTRSViatris to Report Second-Quarter 2026 Financial Results on August 6, 2026
Viatris Inc. has announced that it will report its second-quarter 2026 financial results on August 6, 2026. A conference call and live webcast will be held at 8:30 a.m. ET to discuss these results. Investors and the public can access the call via a dedicated website or by phone.
Read more →VTRSViatris Announces Positive Top-Line Results from Phase 3 Study of VR-205 in Japanese Adults with Primary Immunoglobulin A Nephropathy
Viatris announced positive top-line results from a Phase 3 trial of VR-205 in Japanese adults with primary IgAN. The study met its primary endpoint, showing a significant reduction in urine protein-to-creatinine ratio and improvements in kidney function. The treatment was well tolerated, with no participants progressing to severe renal impairment. Viatris plans to submit a New Drug Application in Japan by the end of 2026.
Read more →VTRSU.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain
Viatris announced that the FDA has accepted its New Drug Application for MR-107A-02, a fast-acting meloxicam aimed at treating moderate-to-severe acute pain. The FDA has set a PDUFA goal date of December 27, 2026. The NDA is backed by positive results from Phase 3 trials, demonstrating effective pain relief and a reduction in opioid usage. This development addresses a critical public health need for non-opioid pain management solutions.
Read more →VTRS▲ +9%on this news
Viatris Reports First-Quarter 2026 Financial Results
Viatris Inc. reported strong financial results for the first quarter of 2026, highlighting disciplined execution across global operations. CEO Scott A. Smith noted growth in key markets and reaffirmed the company's financial guidance for the year. The company anticipates generating significant cash, providing flexibility for capital allocation. Viatris is focused on enhancing its growth profile through new product launches and pipeline advancements.
Read more →VTRS▲ +9%on this newsshared move
Viatris to Present at the Bank of America Securities 2026 Healthcare Conference
Viatris Inc. has announced its participation in the Bank of America Securities 2026 Healthcare Conference, scheduled for May 12, 2026. The presentation will be accessible via a live webcast, with an archived version available afterward. This event reflects Viatris's ongoing commitment to healthcare innovation and investor relations.
Read more →VTRS▲ +9%on this newsshared move
Document Viatris Reports First-Quarter 2026 Financial Results Delivers Total Revenues of $3.5 Billion, Representing 8% Reported Growth Compared to First Quarter 2025, and U.S. GAAP Net Earnings of $176 Million Total Reve
Viatris Inc. reported strong first-quarter 2026 financial results, with total revenues of $3.5 billion, reflecting an 8% growth year-on-year. The company demonstrated solid operating leverage as adjusted EBITDA increased by 10% compared to the same quarter in 2025. Positive contributions from new product launches and strong performance in Greater China significantly boosted sales. Viatris reaffirmed its financial guidance for 2026, highlighting an expected cash generation exceeding $2.5 billion.
Read more →VTRSViatris Announces Quarterly Dividend
Viatris Inc. announced a quarterly dividend of $0.12 per share, payable on June 17, 2026, to shareholders of record by May 22, 2026. This decision reflects the company's ongoing commitment to shareholder value. However, the announcement includes forward-looking statements that highlight potential risks and uncertainties that could affect future performance.
Read more →VTRSViatris Announces Chief Financial Officer Transition
Viatris Inc. announced the departure of Chief Financial Officer Theodora Mistras, who will leave for a new opportunity. Paul Campbell, the current Chief Accounting Officer, has been appointed as interim CFO effective May 8, 2026. Mistras will assist in the transition until May 22, 2026. The company is set to release its first-quarter financial results on May 7, 2026.
Read more →VTRSForward-Looking Statements This press release includes statements that constitute "forward-looking statements." These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform
Viatris announced a transition in its Chief Financial Officer position, with Theodora 'Doretta' Mistras set to depart for a new opportunity. Paul Campbell, the current Chief Accounting Officer, has been appointed as the interim CFO effective May 8, 2026. Mistras will facilitate the transition until May 22, 2026, as the company seeks a permanent successor. The announcement emphasizes the company's preparation for sustainable growth and Campbell's expertise as crucial for continuity during this transition.
Read more →VTRSViatris Announces Several Data Presentations on Investigational Low-Dose Estrogen Combined Hormonal Contraceptive Weekly Patch at the 2026 American College of Obstetricians and Gynecologists Annual Clinical & Scientific Meeting
Viatris Inc. announced the presentation of six abstracts on its investigational low-dose estrogen combined hormonal contraceptive weekly patch at the 2026 ACOG Annual Clinical & Scientific Meeting. The presentations will showcase positive Phase 3 study results, including efficacy, safety, and adhesion performance. The FDA has accepted the New Drug Application for this patch, targeting a decision by July 30, 2026.
Read more →VTRSViatris to Report First Quarter 2026 Financial Results on May 7, 2026
Viatris Inc. has announced that it will report its first quarter 2026 financial results on May 7, 2026. The company will hold a webcast at 8:30 a.m. ET to discuss these results, inviting both investors and the public to participate. A replay of the webcast will be available on their website.
Read more →VTRSViatris Announces Multiple Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting
Viatris Inc. announced the presentation of four abstracts at the 2026 ASCRS Annual Meeting, focusing on various ophthalmology studies. Highlights include full results from the Phase 3 VEGA-3 study on MR-141 for presbyopia and a Phase 1 study of varenicline nasal spray. The company also supports an educational symposium on pharmacological vision correction.
Read more →VTRSViatris Advances Innovative Portfolio with Approval of Effexor® in Japan for Adults with Generalized Anxiety Disorder (GAD)
Viatris has received approval from Japan's Ministry of Health for Effexor® SR as the first treatment for adults with generalized anxiety disorder (GAD). This approval addresses a significant unmet need in Japan, where GAD affects approximately 7.6% of the population. The approval is based on a successful Phase 3 trial demonstrating the drug's efficacy and safety profile.
Read more →VTRSViatris to Outline its Vision for Sustained Revenue and Earnings Growth Through 2030 Growing Base Business Evolving Into More Durable Portfolio of Higher-Margin Generics, Value-Added Medicines and Established Brands Expecting...
Viatris Inc. outlined its strategic vision for sustained revenue and earnings growth through 2030 during its recent Investor Event. The company expects a compound annual growth rate (CAGR) of 5% to 6% for total revenues and anticipates more than $11 billion in cash available for deployment. CEO Scott A. Smith emphasized the importance of their diversified portfolio and a promising innovative pipeline. However, the long-term targets are accompanied by numerous risks and uncertainties that could affect actual outcomes.
Read more →VTRS▼ -5.2%on this news
Viatris Reports Fourth-Quarter and Full-Year 2025 Financial Results
Viatris Inc. announced robust financial results for Q4 and full year 2025, highlighting strong execution and a strategic review aimed at enhancing growth. The company anticipates continued operational growth in 2026, alongside significant cost savings. However, restructuring activities will involve workforce reductions and substantial pre-tax charges.
Read more →VTRS▼ -5.2%on this newsshared move
Viatris Maintains Dividend Policy for 2026 and Announces Quarterly Dividend
Viatris Inc. has announced a dividend policy for 2026, setting the dividend at $0.48 per share, with a quarterly payment of $0.12. This decision reflects the company's commitment to returning value to shareholders, marking the sixth consecutive year of dividend payments. The dividend will be payable on March 18, 2026, to shareholders of record by March 9, 2026.
Read more →VTRS▼ -5.2%on this newsshared move
Document Viatris Reports Fourth-Quarter and Full-Year 2025 Financial Results Reports Fourth-Quarter Total Revenues of $3.7B and Full-Year 2025 Total Revenues of $14.3B Meets or Exceeds 2025 Financial Guidance Across All
Viatris Inc. reported robust financial results for the fourth quarter and full year 2025, exceeding financial guidance across key metrics. Total revenues for the fourth quarter were $3.7 billion, demonstrating a 5% increase year-over-year, while overall 2025 revenues totaled $14.3 billion. The company announced the completion of its strategic review, anticipates substantial net cost savings, and plans to reinvest in growth areas. Despite a U.S. GAAP net loss of $(340) million in Q4, management expressed optimism about operational growth moving into 2026.
Read more →VTRSFDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia
Viatris announced that the FDA has accepted its supplemental New Drug Application for MR-141, a phentolamine ophthalmic solution aimed at treating presbyopia. The FDA has set a PDUFA goal date of October 17, 2026. The application is backed by positive results from Phase 3 trials, indicating a promising new treatment for age-related vision issues.
Read more →VTRSViatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026
Viatris Inc. announced it will report its fourth quarter and full year 2025 financial results on February 26, 2026. The company will also host an investor event on March 19, 2026, in New York City, with details to be shared during the February call. Investors can access the results and events via a live webcast.
Read more →VTRSMapi Pharma to Present New Safety and Efficacy Data from Glatiramer Acetate Depot Long-Acting Injection Phase II Study in Patients with Primary Progressive Multiple Sclerosis (PPMS) at ACTRIMS Forum 2026
Mapi Pharma will present new data from the GA Depot Phase II study for primary progressive multiple sclerosis (PPMS) at ACTRIMS Forum 2026. The study demonstrated promising results, with a high disability progression-free rate and stable physical function among patients. GA Depot, an injectable treatment, has received GMP approval for a Phase III study and aims to address significant unmet medical needs in PPMS.
Read more →VTRSViatris Appoints Matthew J. Maletta as Chief Legal Officer
Viatris Inc. has appointed Matthew J. Maletta as Chief Legal Officer, effective February 9, 2026. He succeeds Brian Roman, who has served the company for over 20 years and will assist with the transition until April 1, 2026. Maletta's extensive legal background includes leadership roles at Endo and Allergan, positioning him well for his new role at Viatris.
Read more →VTRSViatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure
Viatris has launched Inpefa® (sotagliflozin) in the UAE, marking its first commercialization of this innovative treatment for heart failure. This dual SGLT1/2 inhibitor aims to reduce cardiovascular risks in patients with heart failure and type 2 diabetes. Future launches are planned in various countries, expanding access to this critical therapy. The approval is backed by pivotal Phase 3 trials demonstrating significant efficacy in reducing major cardiovascular events.
Read more →VTRSViatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer
Viatris Inc. has appointed Lara Ramsburg as Chief People and Corporate Affairs Officer. This new role combines responsibilities for advancing the company's culture and enhancing stakeholder communication. Ramsburg, with over 25 years of experience, aims to focus on employee engagement and organizational growth as Viatris continues its strategic transformation.
Read more →VTRSViatris Provides Pipeline Update on Four Regulatory Milestones Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced four recent regulatory milestones spanning across all stages of its global...
Viatris Inc. (Nasdaq: VTRS) announced four significant regulatory milestones related to its global pipeline, highlighting achievements in research and development for the year 2025. The company received approvals for multiple injectable medications, expanding its product offerings and solidifying its capacity to navigate complex regulatory landscapes. Among the updates, a new once-weekly contraceptive patch and an innovative gene therapy platform for treating neurotrophic keratopathy were disclosed, showcasing Viatris' commitment to addressing unmet medical needs. The company aims to continue its progress in partnership with health authorities worldwide as it moves into 2026.
Read more →VTRSViatris to Present at the 44th Annual J.P. Morgan Healthcare Conference
Viatris Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. The event will feature a presentation and a fireside chat, starting at 9 a.m. PT. A live webcast will be available, along with an archived version post-event. Viatris aims to bridge generics and brands to enhance global healthcare access.
Read more →VTRSViatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited
Viatris has entered into agreements to sell its equity stake in Biocon Biologics for $815 million, comprising $400 million in cash and $415 million in equity shares. This transaction not only strengthens Viatris' financial position but also allows the company to re-enter the biosimilars market. The deal is expected to close in Q1 2026, subject to conditions.
Read more →VTRSViatris to Participate in Upcoming Investor Conferences
Viatris Inc. has announced its participation in two upcoming healthcare conferences in December 2025. The company will engage in fireside chats at the Piper Sandler 37th Annual Healthcare Conference and the Evercore 8th Annual Healthcare Conference. Both sessions will be accessible to investors and the public, with archived versions available post-event.
Read more →VTRSCaída de precios, aumento de costes y escasez: conclusiones de un estudio de Viatris y Medicines for EuropeUSA - españolUSA - EnglishUSA - PolskiUSA - DeutschUSA - FrançaisUSA - slovenčinaUSA - češtinaUSA - Pусский
A study presented by Viatris and Medicines for Europe highlights the decline in antibiotic prices, rising manufacturing costs, and the resulting scarcity of essential off-patent medicines. The report calls for urgent reforms in pricing and procurement policies to ensure patient access to these critical treatments. It underscores the potential public health risks posed by the current trends in antibiotic availability.
Read more →VTRSЕвропейское исследование показывает падение цен, рост затрат и дефицит -- результаты независимого исследования, представленного Viatris и Medicines for Europe на Всемирной неделе осведомленности об УППUSA - PусскийUSA - češtinaUSA - PolskiUSA - FrançaisUSA - slovenčinaUSA - DeutschUSA - EnglishUSA - español
A recent study presented by Viatris and Medicines for Europe during World Antibiotic Awareness Week reveals concerning trends in antibiotic access in Europe. The report indicates a decline in prices and rising production costs, which may jeopardize patient access to essential medications. It calls for urgent reforms in national pricing systems to ensure sustainable access to antibiotics and other off-patent medicines.
Read more →VTRSEurópska štúdia zisťuje klesajúce ceny, rastúce náklady a nedostatky - Viatris a Medicines for Europe prezentujú nezávislú štúdiu počas Svetového týždňa povedomia o antimikrobiálnej rezistencii (AMR)USA - slovenčinaUSA - EnglishUSA - PolskiUSA - DeutschUSA - FrançaisUSA - češtinaUSA - PусскийUSA - español
During World Antimicrobial Awareness Week, Viatris and Medicines for Europe presented findings from a study highlighting the challenges of ensuring access to off-patent medicines, especially antibiotics. The study calls for urgent reforms in national pricing and procurement systems to maintain drug availability. It warns that rising production costs and declining prices could jeopardize public health and exacerbate antimicrobial resistance.
Read more →VTRSUne étude européenne révèle une baisse des prix, une augmentation des coûts et des pénuries - conclusions d'une étude indépendante présentées par Viatris et Medicines for Europe lors de la Semaine mondiale de sensibilisation à la résistance aux antimicrobiens.USA - FrançaisUSA - češtinaUSA - PolskiUSA - slovenčinaUSA - DeutschUSA - EnglishUSA - PусскийUSA - español
During the World Antimicrobial Awareness Week, Viatris and Medicines for Europe presented findings from an independent study highlighting the urgent need for reforms in the pricing and supply systems of off-patent medicines, particularly antibiotics. The study indicates that decreasing prices and rising manufacturing costs threaten the availability of these essential drugs, risking public health and exacerbating antimicrobial resistance. The organizations urge policymakers to implement sustainable systems to ensure patient access to these critical treatments.
Read more →VTRSEuropäische Studie zeigt sinkende Preise, steigende Kosten und Engpässe - Ergebnisse einer unabhängigen Studie, die während der World AMR Awareness Week von Viatris und Medicines for Europe vorgestellt wurdenUSA - DeutschUSA - EnglishUSA - PусскийUSA - españolUSA - češtinaUSA - PolskiUSA - FrançaisUSA - slovenčina
During the World AMR Awareness Week, Viatris and Medicines for Europe presented a study highlighting the urgent need for reforms in pricing and procurement systems to ensure access to off-patent antibiotics. The study reveals that while prices are declining, manufacturing costs are rising, jeopardizing the availability of essential medicines. The findings underscore the critical role of antibiotics in public health and call for immediate policy action.
Read more →VTRSEuropejskie badanie pokazuje spadające ceny, rosnące koszty i niedobory - wyniki niezależnego badania przedstawione podczas Światowego Tygodnia Wiedzy o Antybiotykach przez firmę Viatris i organizację Medicines for EuropeUSA - PolskiUSA - EnglishUSA - DeutschUSA - FrançaisUSA - slovenčinaUSA - češtinaUSA - PусскийUSA - español
During World Antibiotic Awareness Week, Viatris and Medicines for Europe presented findings from an independent study on the causes of essential medicine shortages, particularly antibiotics. The report highlights the need for reforms in national pricing and procurement systems to ensure patient access. Rising production costs and declining prices threaten the availability of these crucial medications, necessitating immediate action from policymakers.
Read more →VTRSEuropean study shows falling prices, rising costs and shortages - findings from independent study presented during World AMR Awareness Week by Viatris and Medicines for EuropeUSA - EnglishUSA - PolskiUSA - DeutschUSA - FrançaisUSA - slovenčinaUSA - češtinaUSA - PусскийUSA - español
During World AMR Awareness Week, Viatris and Medicines for Europe presented findings from an independent study that highlights the critical need for policy reforms to ensure access to off-patent antibiotics in Europe. The study reveals that while prices are decreasing, production costs are rising, threatening the availability of these essential medicines. The report calls for urgent action from policymakers to secure sustainable access to antibiotics and improve public health outcomes.
Read more →VTRSEvropská studie ukazuje klesající ceny, rostoucí náklady a nedostatek - výsledky nezávislé studie představené během Světového týdne povědomí o antimikrobiální rezistenci společnostmi Viatris a Medicines for Europe V rámci Světového týdne povědomí o antimikrobiální rezistenci (AMR) ukazuje zpráva Světové zdravotnické organizace o globálním sledování antibiotické ...
V rámci Světového týdne povědomí o antimikrobiální rezistenci (AMR) byla představena nezávislá studie zkoumá účinky poklesu cen antibiotik a rostoucí výrobní náklady. Studie, sponzorovaná společnostmi Viatris a Medicines for Europe, varuje před hrozícím nedostatkem základních nepatentovaných léků. Autoři zdůrazňují nutnost reformy cenových politik a dodavatelských systémů, aby byla zajištěna dostupnost životně důležitých léků pro pacienty v Evropě. Snížená dostupnost by mohla vést k výraznému zhoršení veřejného zdraví a zvýšení antimikrobiální rezistence.
Read more →VTRSViatris Recognized as One of the Fortune World's Best Workplaces™ in 2025 Viatris Inc. (Nasdaq: VTRS) today announced that it has been recognized as one of the Fortune World's Best Workplaces™ in 2025. The list of 25 global ...
Viatris Inc. has been recognized as one of the Fortune World's Best Workplaces for 2025, showcasing its commitment to creating a positive work environment. The selection was based on extensive employee feedback collected through Great Place To Work's survey, evaluating companies globally on their workplace culture. Viatris' inclusion on this prestigious list highlights its efforts in promoting wellbeing, inclusion, and professional growth among its employees. This recognition adds to the company's accolades, including its presence on Forbes' World's Best Employers list and TIME's World's Most Sustainable Companies list.
Read more →VTRS▼ -6%on this news
Viatris Reports Third Quarter 2025 Results and Updates 2025 Financial Guidance
Viatris Inc. reported strong financial results for Q3 2025, with total revenues of $3.76 billion, reflecting a slight increase from the previous year. The company has updated its financial guidance for 2025, raising expectations primarily due to foreign exchange and share repurchases. However, it also reported a net loss of $128.2 million for the quarter, influenced by a significant goodwill impairment charge.
Read more →VTRS▼ -6%on this newsshared move
Document Viatris Reports Third Quarter 2025 Results and Updates 2025 Financial Guidance Delivers Total Revenues in Line With Expectations, Reflecting Strong Execution of its Global Business Makes Late-Stage Pipeline Prog
Viatris Inc. (VTRS) reported its third-quarter financial results for 2025, revealing total revenues of $3.8 billion, consistent with expectations despite a slight operational decline. The company updated its financial guidance, highlighting strong performance in key emerging markets and successful acquisitions, such as Aculys Pharma. However, it also experienced a net loss of $128 million in the quarter, contrasting sharply with earnings in Q3 2024, primarily due to investment and tax expenses. The firm plans to continue advancing its pipeline, including regulatory submissions for new products.
Read more →VTRSViatris Announces Quarterly Dividend Viatris Inc. (Nasdaq: VTRS) today announced that on November 3, 2025, its Board of Directors declared a quarterly dividend of $0.12 per share for...
Viatris Inc. has announced a quarterly dividend of $0.12 per share, which will be payable on December 15, 2025, to shareholders of record as of November 24, 2025. This declaration was made by the company's Board of Directors on November 3, 2025. Viatris, a global healthcare company, focuses on supplying high-quality medicines to enhance healthcare access for patients worldwide.
Read more →VTRSViatris Completes Acquisition of Aculys Pharma Including Exclusive Rights to Pitolisant in Japan and to Spydia® in Japan and Certain Other Markets in the Asia-Pacific Region Strengthens Viatris' Presence in Japan With the Addition of Two Innovative Assets Targeting Areas of Significant Unmet Medical Need Leverages...
Viatris Inc. has completed the acquisition of Aculys Pharma, gaining exclusive rights to develop and commercialize pitolisant and Spydia in Japan and other Asia-Pacific markets. This acquisition aims to address significant unmet medical needs in neurological conditions, with plans to file for marketing approval for pitolisant by the end of 2025. Recent Phase 3 trials have shown positive outcomes in Japanese patients for both drugs, aligning with Viatris' strategic vision to broaden its innovative product offerings in Japan. The deal also includes contingent payments based on regulatory milestones.
Read more →VTRSViatris to Participate in Upcoming Investor Conferences Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will participate in two upcoming healthcare conferences in ...
Viatris Inc. has announced its participation in two significant healthcare conferences scheduled for November 2025. The company will host a fireside chat at the UBS Global Healthcare Conference on November 11 and another at the Jefferies Global Healthcare Conference in London on November 18. Investors and the public can listen to these events live and access them later through Viatris' investor website. This participation highlights Viatris' focus on empowering global healthcare access and engagement.
Read more →VTRSViatris Named to Forbes' Annual List of the World's Best Employers for the Fifth Year in a Row Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that it has been named to Forbes' list of World's Best Employers 2025. This ...
Viatris Inc. has been named to Forbes' list of the World's Best Employers for 2025, marking its fifth consecutive year on the prestigious list. This recognition reflects the company's dedication to workplace well-being, inclusivity, and career development, as stated by Chief Administrative Officer Andrew Enrietti. The selection was based on a survey of over 300,000 participants evaluating their employers across various criteria. Additionally, Viatris has also received accolades from TIME and Great Place to Work for its initiatives in sustainability and employee satisfaction.
Read more →VTRSViatris to Report Third Quarter 2025 Financial Results on November 6, 2025 Viatris Inc. (Nasdaq: VTRS) will report third quarter 2025 financial results on Thursday, November 6, 2025. Company executives will host a webcast at ...
Viatris Inc. (Nasdaq: VTRS) is scheduled to report its financial results for the third quarter of 2025 on November 6, 2025. A live webcast will be hosted by company executives at 8:30 a.m. ET, available to both investors and the general public. The webcast will allow participants to understand the company's financial performance during the quarter.
Read more →VTRSViatris Appoints Andrew Enrietti as Chief Administrative and Transformation Officer Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced the appointment of Andrew Enrietti as Chief Administrative and...
Viatris Inc. has announced the appointment of Andrew Enrietti as Chief Administrative and Transformation Officer, a newly established position aimed at overseeing key operational areas including human relations and information technology. This appointment is part of a broader strategy to centralize leadership and accelerate the company’s transformation efforts. Enrietti's extensive experience with Viatris positions him well to lead these initiatives, as he aims to enhance organizational effectiveness and support long-term growth. Both Enrietti and CEO Scott A. Smith emphasized the importance of this role in shaping Viatris's future.
Read more →VTRSViatris Announces Approval of First Generic Iron Sucrose Injection in the U.S. Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced the U.S. Food and Drug Administration (FDA) has approved Iron Sucrose...
Viatris Inc. announced FDA approval for Iron Sucrose Injection, the first generic version for treating iron deficiency anemia in chronic kidney disease patients. The approval includes strengths of 50 mg/2.5mL, 100mg/5mL, and 200mg/10mL, with expectations for immediate availability. The drug's Competitive Generic Therapy designation allows for expedited market entry and 180 days of exclusivity. This approval reflects Viatris' commitment to addressing patient needs by expanding their complex generics portfolio.
Read more →VTRS▲ +7.3%on this newsshared move
Document Viatris Reports Second Quarter 2025 Results and Reiterates 2025 Financial Guidance Delivers Total Revenues Above Expectations Reflecting the Strength of our Execution and the Resilience of our Diversified Global
Viatris Inc. (Nasdaq: VTRS) reported strong second quarter 2025 results, with total revenues of $3.6 billion, exceeding expectations despite a 6% drop from the previous year. The company reiterated its financial guidance for 2025 while highlighting encouraging momentum in its late-stage pipeline, marked by positive outcomes from five Phase 3 studies this year. CEO Scott A. Smith emphasized the firm’s strategic priorities and capital returns exceeding $630 million year-to-date. However, total revenues faced pressure due to the negative Indore impact.
Read more →VTRS▲ +7.3%on this newsshared move
Viatris Reports Second Quarter 2025 Results and Reiterates 2025 Financial Guidance Delivers Total Revenues Above Expectations Reflecting the Strength of our Execution and the Resilience of our Diversified Global Business Positive...
Viatris Inc. reported strong financial results for the second quarter of 2025, exceeding expectations and reaffirming its financial guidance for the year. The company highlighted encouraging momentum in its late-stage pipeline and significant capital returns to shareholders, exceeding $630 million year-to-date. However, despite these positive aspects, total revenues decreased by 6% compared to the previous year, and the company reported a U.S. GAAP net loss in the quarter. Viatris remains confident in its strategic execution and growth prospects for 2026 and beyond.
Read more →VTRSViatris Announces Appointment of David Simmons to the Company's Board of Directors PITTSBURGH
Viatris Inc. has appointed David Simmons to its Board of Directors. Simmons, who has a robust background in the pharmaceutical industry, previously served as CEO of PPD, Inc., where he significantly increased the company's value. His experience includes strategic roles at Pfizer and extensive board service in various healthcare organizations. Both Viatris' Chair and CEO express confidence that Simmons will add value and aid in achieving the company's strategic goals.
Read more →VTRSViatris Announces Quarterly Dividend Viatris Inc. (Nasdaq: VTRS) today announced that on August 4, 2025, its Board of Directors declared a quarterly dividend of $0.12 per share for each...
Viatris Inc. has announced a quarterly dividend of $0.12 per share, which was declared by the Board of Directors on August 4, 2025. The dividend will be payable on September 15, 2025, for shareholders on record by August 22, 2025. This financial decision underscores the company's ongoing commitment to providing returns to its shareholders while continuing to serve a global market with a diverse portfolio of healthcare solutions.
Read more →VTRSViatris Announces Five Data Presentations on Novel Fast-Acting Meloxicam (MR-107A-02) at PAINWeek 2025 Conference Viatris (Nasdaq: VTRS), a global healthcare company, today announced that five abstracts from its Phase 3 program evaluating novel fast-acting...
Viatris has announced that five abstracts from its Phase 3 program on the novel fast-acting meloxicam (MR-107A-02) will be presented at the upcoming PAINWeek 2025 conference in Las Vegas. The presentations will cover various aspects, including efficacy, safety, and opioid use reduction in moderate-to-severe acute surgical pain models. Key studies involve surgeries such as herniorrhaphy and bunionectomy, highlighting positive results. This development is aimed at enhancing pain management while reducing reliance on opioids.
Read more →VTRSViatris Provides Update on Phase 3 Study of MR-139 for Blepharitis Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that a randomized, double-masked, vehicle-controlled, Phase 3 study to...
Viatris Inc. reported that its Phase 3 study of MR-139 for treating blepharitis failed to achieve the primary endpoint of complete debris resolution after six weeks. The trial included 477 patients and evaluated the effectiveness of the ophthalmic ointment. Following the study, Viatris's Chief R&D Officer indicated that the company is assessing future steps in the MR-139 program. Despite this setback, Viatris has noted positive results from other trials in its pipeline.
Read more →VTRSViatris Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141 in Presbyopia Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced positive top-line results from VEGA-3, the second pivotal Phase 3 trial...
Viatris has announced positive top-line results from the VEGA-3 Phase 3 trial of MR-141, focusing on presbyopia treatment. The trial showed that MR-141 met all clinical endpoints and improved near visual acuity without compromising distance vision. The safety profile of MR-141 was consistent with previous studies, without any serious adverse events. Viatris plans to submit an application to the U.S. FDA in the second half of 2025 for potential approval.
Read more →VTRSViatris to Report Second Quarter 2025 Financial Results on August 7, 2025 Viatris Inc. (Nasdaq: VTRS) will report second quarter 2025 financial results on Thursday, August 7, 2025. Company executives will host a webcast at...
Viatris Inc. (Nasdaq: VTRS) will announce its second quarter 2025 financial results on August 7, 2025. The announcement will be followed by a webcast hosted by company executives to discuss the outcomes. Investors and the public can participate in the webcast via the company's investor website or through a conference call. Viatris promotes its role in providing healthcare by connecting generic and brand medicines, emphasizing its global reach and diverse portfolio.
Read more →VTRSViatris Announces Positive Top-Line Results from Phase 3 LYNX-2 Trial of MR-142 in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions MR-142 Achieved Primary Endpoint of ≥15-letter (≥3-line) Gain in Mesopic Low Contrast Distance Visual Acuity in Comparison to Placebo Results Showed...
Viatris Inc. has announced positive top-line results from its Phase 3 LYNX-2 trial evaluating MR-142, a treatment for chronic night driving impairment in keratorefractive patients. The trial demonstrated a statistically significant gain in distance visual acuity compared to placebo, marking a potential breakthrough as no FDA-approved therapies currently exist for this condition. The study was conducted under FDA Special Protocol Assessment and received Fast Track designation, which may accelerate its development and review process. A follow-up study, LYNX-3, is set to begin soon, with results expected in early 2026.
Read more →VTRS▲ +5.7%on this news
Viatris Reports First Quarter 2025 Results and Reaffirms 2025 Outlook Viatris Inc. (Nasdaq: VTRS) today reported first quarter 2025 financial results and reaffirmed its 2025 outlook[1]. Executive...
Viatris Inc. reported its first quarter 2025 financial results, showing a revenue decline of 11% year-over-year. Despite this, the company reaffirmed its 2025 outlook, expecting revenues to range between $13.5 billion and $14 billion. Leadership highlighted a strong cash flow, with over $300 million in share repurchases, while emphasizing confidence in navigating industry volatility. However, the company also reported a significant net loss attributed to a goodwill impairment charge.
Read more →VTRS▲ +5.7%on this news
Viatris Announces Positive Results from Phase 3 Study of Investigational XULANE LO™ Low Dose Patch for Birth Control in Women of Childbearing Potential Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced positive results of its Phase 3 study (NCT05139121) evaluating the...
Viatris Inc. announced positive results from its Phase 3 study of the investigational XULANE LO low dose weekly dermal patch for contraception. The study included 1,272 women and evaluated efficacy and safety over 13 cycles, demonstrating a favorable profile with no new safety concerns. The company anticipates submitting a New Drug Application to the FDA in the second half of 2025, highlighting the patch's potential to meet the needs of women seeking lower estrogen dosage options.
Read more →VTRS▲ +5.7%on this news
Viatris Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of Novel Fast-Acting Meloxicam (MR-107A-02) for the Treatment of Moderate-to-Severe Acute Pain Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced positive results from its Phase 3 program of the novel fast-acting...
Viatris Inc. announced positive top-line results from two pivotal Phase 3 studies of MR-107A-02, a fast-acting meloxicam formulation for moderate-to-severe acute pain. Both studies achieved all primary and secondary endpoints, demonstrating significant pain relief and reduced opioid use compared to existing treatments. Viatris plans to submit a New Drug Application to the FDA targeting a submission by the end of 2025. The results mark an important step towards providing a non-opioid analgesic option for patients in need of effective pain management.
Read more →VTRS▲ +5.7%on this news
Document Viatris Reports First Quarter 2025 Results and Reaffirms 2025 Outlook Delivers Total Revenues in Line With Expectations Demonstrating Strength of the Base Business Makes Significant Pipeline Progress With Three
Viatris Inc. reported its first quarter 2025 results, reaffirming its outlook for the year amid significant pipeline progress. The financial results revealed total revenues of $3.3 billion, down 11% from the previous year, largely due to a goodwill impairment charge of $2.9 billion. Despite challenges, the company highlighted strong cash flow, capital discipline, and plans to return over $450 million to shareholders. Positive developments include advancements in several Phase 3 studies, positioning Viatris for potential growth in new product revenues and market opportunities.
Read more →VTRSViatris Announces Quarterly Dividend Viatris Inc. (Nasdaq: VTRS) today announced that on May 5, 2025, its Board of Directors declared a quarterly dividend of $0.12 per share for each...
Viatris Inc. has announced a quarterly dividend of $0.12 per share, set to be paid on June 16, 2025, to shareholders of record by May 23, 2025. This decision reflects the company's commitment to delivering value to its shareholders. Viatris is positioned as a global healthcare company, aiming to provide high-quality medicines and address healthcare needs at various life stages.
Read more →VTRSViatris Announces Appointments of Frank D'Amelio and Michael Severino, M.D., to the Company's Board of Directors Directors Rajiv Malik and Harry Korman to Retire at the End of Their Current Terms PITTSBURGH
Viatris Inc. has announced the appointments of Frank D'Amelio and Michael Severino, M.D., to its Board of Directors as part of ongoing efforts to refresh its governance. The company will also see the retirement of directors Rajiv Malik and Harry Korman at the conclusion of their terms in December following the 2025 Annual Meeting. D'Amelio and Severino bring significant experience in the pharmaceutical industry, with backgrounds that include leadership roles at major firms such as Pfizer and AbbVie. The Board's chairperson and CEO expressed optimism about the new appointments and gratitude for the contributions of the retiring members.
Read more →VTRSViatris to Present at the BofA Securities 2025 Healthcare Conference Viatris Inc. (Nasdaq: VTRS), a global healthcare company, will present at the BofA Securities 2025 Healthcare Conference in Las Vegas, NV, on...
Viatris Inc. (Nasdaq: VTRS) has announced its upcoming presentation at the BofA Securities 2025 Healthcare Conference scheduled for May 13, 2025, in Las Vegas. The company aims to highlight its global healthcare mission and extensive portfolio. A live webcast of the event will be available, with an archived version accessible afterwards on their investor website. Viatris is positioned to address global healthcare needs, providing high-quality medicines to around 1 billion patients annually.
Read more →VTRSViatris Files Supplemental New Drug Applications to Japan's Ministry of Health, Labor and Welfare for the Approval of EFFEXOR® for the Treatment of Generalized Anxiety Disorder Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it has filed applications to the Ministry of Health, Labor and Welfare...
Viatris Inc. has submitted supplemental New Drug Applications to Japan's Ministry of Health, Labor and Welfare for EFFEXOR (venlafaxine hydrochloride) aimed at treating generalized anxiety disorder (GAD) in adults. The drug has shown positive results in Phase 3 studies, achieving its primary objective of demonstrating superior anxiolytic effects compared to a placebo. Currently, there is no approved treatment for GAD in Japan, and the filing marks a significant milestone in addressing this unmet medical need.
Read more →VTRSViatris Appoints Hemanth J. Varghese as Chief Strategy Officer Viatris Inc. (Nasdaq: VTRS) today announced that Hemanth J. Varghese has joined the Company as Chief Strategy Officer. Varghese will be a member of...
Viatris Inc. has announced the appointment of Hemanth J. Varghese as Chief Strategy Officer. Varghese brings over 20 years of experience in strategy and operations, having previously held high-ranking positions at various healthcare companies. His leadership is expected to contribute significantly to Viatris's growth and transformation as the company reinforces its strategic direction for the future. CEO Scott A. Smith expressed enthusiasm about Varghese's role in shaping the company’s trajectory going forward.
Read more →VTRSViatris Statement on Nationwide Settlement to Resolve Opioid-Related Claims Viatris Inc. (Nasdaq: VTRS) (the Company ) today announced it has reached a nationwide settlement framework to resolve opioid-related claims by...
Viatris Inc. announced a nationwide settlement framework to resolve opioid-related claims from various governmental entities. The settlement involves up to $335 million paid over nine years, aimed at supporting opioid-related efforts. Importantly, the company states that this settlement does not indicate any admission of liability. Viatris will continue to focus on addressing public health challenges, including providing access to important medications.
Read more →VTRSViatris to Report First Quarter 2025 Financial Results on May 8, 2025 Viatris Inc. (NASDAQ: VTRS) will report first quarter 2025 financial results on Thursday, May 8, 2025. Company executives will host a webcast at 8:30 ...
Viatris Inc. (NASDAQ: VTRS) is set to report its financial results for the first quarter of 2025 on May 8, 2025. The announcement includes a webcast hosted by company executives at 8:30 a.m. ET for both investors and the public. This webcast will offer an opportunity to discuss the company's performance and strategic initiatives. Viatris is known for its role in bridging generics and branded medications effectively, serving approximately 1 billion patients globally each year.
Read more →VTRSViatris to Present at the Barclays 27th Annual Global Healthcare Conference Viatris Inc. (NASDAQ: VTRS), a global healthcare company, will present at the Barclays 27th Annual Global Healthcare Conference in Miami Beach, FL on ...
Viatris Inc. is set to present at the Barclays 27th Annual Global Healthcare Conference on March 11, 2025, in Miami Beach, Florida. The presentation will be held at 2 p.m. ET and will feature a fireside chat format. A live webcast will be available, along with an archived version post-event. Viatris continues to emphasize its global mission to provide high-quality medicines across various healthcare needs.
Read more →VTRS▼ -15.2%on this news
Document Viatris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Financial Guidance Meets 2024 Guidance for Total Revenues, Adjusted EBITDA and Adjusted EPS Exceeds 2024 Guidance for Free Ca
Viatris reported its fourth quarter and full year 2024 financial results, highlighting total revenues of $14.7 billion with a U.S. GAAP net loss of $634 million. Despite these losses, the company exceeded its guidance for free cash flow, reaching $2.0 billion. For 2025, Viatris aims to prioritize capital returns, including significant share repurchases, while focusing on upcoming Phase 3 data readouts for key pipeline assets. However, the reported decline in total revenues reflects ongoing challenges in both developed and emerging markets.
Read more →VTRS▼ -15.2%on this news
Viatris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Financial Guidance Meets 2024 Guidance for Total Revenues, Adjusted EBITDA and Adjusted EPS; Exceeds 2024 Guidance for Free Cash Flow [1] Reports 2024 Total Revenues of ...
Viatris Inc. announced its financial results for the fourth quarter and full year 2024, reporting total revenues of $14.7 billion and a U.S. GAAP net loss of $634 million. The company met its guidance for total revenues, adjusted EBITDA, and adjusted EPS, with free cash flow exceeding expectations. Looking ahead to 2025, Viatris plans to prioritize capital return to shareholders and focus on advancing its pipeline, including several upcoming Phase 3 data readouts. Despite these positive developments, the company experienced a decline in net sales and significant financial losses over the year.
Read more →VTRS▼ -15.2%on this news
Viatris Maintains Dividend Policy for 2025 and Announces Quarterly Dividend Viatris Inc. (NASDAQ: VTRS) today announced that on February 24, 2025, its Board of Directors approved a 2025 dividend policy of 48 cents ($0.48) per ...
Viatris Inc. announced a dividend policy for 2025, approving a payout of 48 cents per share, along with a quarterly dividend of 12 cents. This decision reflects the company's commitment to returning value to its shareholders. The dividends are payable on March 18, 2025, marking the fifth consecutive year Viatris has issued dividends. The company continues to emphasize its unique position in the global healthcare market.
Read more →VTRSViatris to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025 Viatris Inc. (NASDAQ: VTRS) will report financial results for the fourth quarter and full year 2024 on Thursday, February 27, 2025. Company...
Viatris Inc. (NASDAQ: VTRS) is scheduled to report its financial results for the fourth quarter and full year of 2024 on February 27, 2025. A live webcast will be hosted by company executives at 8:30 a.m. ET on the same day, allowing investors and the public to engage with the results. The webcast will also have a replay available later on the company's website. Viatris continues to serve approximately 1 billion patients annually with its diverse portfolio of medicines.
Read more →VTRSViatris to Present at the 43rd Annual J.P. Morgan Healthcare Conference Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that the company will present at the 43rd Annual J.P. Morgan Healthcare...
Viatris Inc. (NASDAQ: VTRS) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference, scheduled for January 14, 2025. The presentation will feature a fireside chat starting at 8:15 a.m. PT / 11:15 a.m. ET. Interested parties can access a live webcast and an archived version of the presentation on their investor website. Viatris aims to bridge the gap between generics and branded medicines to enhance global healthcare access.
Read more →VTRSViatris Announces Publication of Phase 2b CARE Study Data for Cenerimod in Lancet Rheumatology Viatris Inc. (NASDAQ: VTRS) today announced the publication of Phase 2b CARE study results evaluating the efficacy and safety of cenerimod in adults...
Viatris Inc. announced the publication of Phase 2b CARE study results for cenerimod in adults with moderate-to-severe systemic lupus erythematosus (SLE), showing significant improvements in disease activity. The study, published in Lancet Rheumatology, noted that cenerimod was well-tolerated and had an adverse event profile consistent with its mechanism of action. Additionally, biomarker data further characterized cenerimod's immunomodulatory effects, providing insights into its potential treatment for SLE. This advancement comes as part of the ongoing Phase 3 OPUS program, which aims to evaluate the drug's effectiveness and safety.
Read more →VTRS▲ +13.5%on this news
Document Viatris Reports Third Quarter Financial Results for 2024 Total Revenues of $3.8 Billion and Operational Revenue Growth of 3% on a Divestiture-Adjusted Basis Demonstrate Strength of Company's Base Business 1 Stro
Viatris reported its third quarter financial results for 2024, with total revenues of $3.8 billion and a 3% operational revenue growth on a divestiture-adjusted basis. The company's strong product revenues reached $133 million, contributing positively to its financial stability. However, the results also showed a substantial drop in net earnings and EPS, reflecting challenges faced during the quarter. Despite these setbacks, Viatris remains optimistic, reaffirming its revenue growth outlook for the full year.
Read more →VTRS▲ +13.5%on this news
Viatris Reports Third Quarter Financial Results for 2024 Total Revenues of $3.8 Billion and Operational Revenue Growth of ~3% on a Divestiture-Adjusted Basis Demonstrate Strength of Company's Base...
Viatris Inc. reported total revenues of $3.8 billion for Q3 2024, with operational revenue growth of approximately 3% on a divestiture-adjusted basis. The company also highlighted strong product revenues of $133 million and successful debt repayment of about $1.9 billion. However, U.S. GAAP net earnings saw a significant decline of approximately 71% compared to the previous year, with diluted EPS dropping from $0.27 to $0.08. Despite the challenges, Viatris reaffirms its outlook for continued revenue growth and plans to focus on capital allocation to enhance shareholder value.
Read more →VTRSViatris Announces Third Quarter 2024 Dividend Viatris Inc. (NASDAQ: VTRS) today announced that on November 4, 2024, its Board of Directors declared a quarterly dividend of $0.12 per share for...
Viatris Inc. (NASDAQ: VTRS) has declared a quarterly dividend of $0.12 per share, payable on December 13, 2024, to shareholders recorded by November 22. The announcement highlights the company's ongoing commitment to shareholder returns and financial health. Viatris positions itself as a leading global healthcare provider, aiming to bridge the gap between generics and branded medications. With a mission to improve health access worldwide, Viatris serves approximately 1 billion patients annually.
Read more →VTRSViatris Named to Forbes' World's Top Companies for Women 2024 List Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it has been named to Forbes' World's Top Companies for Women 2024 List....
Viatris Inc. (NASDAQ: VTRS) has been recognized in Forbes' World's Top Companies for Women 2024 list, an accolade awarded in partnership with Statista. This recognition reflects the company’s commitment to diversity, innovation, and the empowerment of women in the workforce. With a focus on fostering an inclusive culture, Viatris strives to invest in its people and support female talent. This achievement follows multiple other recognitions for the company related to sustainability and employee satisfaction.
Read more →VTRSViatris to Participate in the UBS Global Healthcare Conference and Jefferies London Healthcare Conference Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the company will participate in two upcoming healthcare conferences....
Viatris Inc. (Nasdaq: VTRS) announced its participation in the upcoming UBS Global Healthcare Conference and the Jefferies London Healthcare Conference. These events will feature live webcasts available for interested parties and will highlight the company's commitment to bridging generics and brand pharmaceuticals. Viatris aims to empower people worldwide by providing access to quality medicines across various health stages. The company's extensive portfolio and global supply chain positions it uniquely to address healthcare challenges.
Read more →VTRSViatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it has entered into an exclusive licensing agreement with Lexicon...
Viatris Inc. has announced an exclusive licensing agreement with Lexicon Pharmaceuticals for the diabetes treatment sotagliflozin in all markets excluding the U.S. and Europe. The agreement, which includes a $25 million upfront payment among other potential milestones, allows Viatris to utilize its expertise in cardiovascular diseases to expedite the commercialization of sotagliflozin. Both companies expressed optimism about the partnership's potential to enhance patient access and drive growth.
Read more →VTRSViatris Announces Positive Top-line Results from Phase 3 Study of EFFEXOR® in Japanese Adults with Generalized Anxiety Disorder (GAD) Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced positive top-line results of its Phase 3 study (B2411367) in Japan...
Viatris Inc. announced positive top-line results from its Phase 3 study of EFFEXOR (venlafaxine) in Japanese adults with generalized anxiety disorder (GAD). The study, which met its primary goal demonstrating efficacy over placebo, involved 357 patients and showed improvement in anxiety symptoms as measured by the Hamilton Anxiety Rating Scale. The product was well tolerated, aligning with its known safety profile. Viatris plans to submit for regulatory approval in Japan by 2025, addressing a significant gap in available treatments for GAD in the region.
Read more →VTRSViatris Named to Forbes' Annual List of the World's Best Employers for the Fourth Year in a Row Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it has been named to Forbes' list of World's Best Employers 2024. This ...
Viatris Inc. (NASDAQ: VTRS) has been recognized for the fourth consecutive year in Forbes' list of the World's Best Employers for 2024. This accolade is based on an independent survey of over 300,000 participants and underlines Viatris' commitment to fostering a strong workplace culture that prioritizes employee well-being, inclusivity, and career growth. The company has also gained recognition in other significant rankings, affirming its position as a leader in the global healthcare industry.
Read more →VTRSViatris Announces the Pricing Terms of Maximum Tender Offer Viatris Inc. (NASDAQ: VTRS, Viatris or the Company ) announced today the pricing terms of the previously announced cash tender offer (the Maximum ...
Viatris Inc. has announced the pricing terms for its Maximum Tender Offer, aimed at repurchasing up to $575 million of its 3.950% Senior Notes due 2026. As reported, by the Early Tender Date, an aggregate principal amount of $1.45 billion in notes had been tendered, surpassing the maximum amount planned for repurchase, necessitating a pro rata acceptance. With the tender offer set to expire on October 2, 2024, the company has also indicated that conditions surrounding the offer may be waived or altered, posing additional risks for participating holders.
Read more →VTRSViatris Announces Early Tender Results and Increase of Pending Maximum Tender Offer Viatris Inc. (NASDAQ: VTRS, Viatris or the Company ) announced today the early tender results of the previously announced cash tender offer (the...
Viatris Inc. announced the early results of its cash tender offer, increasing the Maximum Tender Offer from $450 million to $575 million for its Senior Notes due 2026. As of the early tender date, approximately $1.45 billion worth of notes were tendered, exceeding the revised cap. This oversubscription means not all tendered notes can be accepted, leading to a pro rata acceptance basis. The offer is set to expire on October 2, 2024, unless extended.
Read more →VTRSViatris to Report Third Quarter 2024 Financial Results on November 7, 2024 Viatris Inc. (NASDAQ: VTRS) will report its third quarter 2024 financial results on Thursday, November 7, 2024, before the open of the U.S. financial ...
Viatris Inc. (NASDAQ: VTRS) is scheduled to report its third quarter 2024 financial results on November 7, 2024, ahead of the U.S. markets opening. CEO Scott A. Smith and executives will host a live webcast at 8:30 a.m. ET to discuss these results, which will be available both via a call and on the company’s investor website. This transparency reflects Viatris's commitment to keeping stakeholders informed about its performance.
Read more →VTRSViatris Announces Expiration and Results of Any and All Cash Tender Offers Viatris Inc. (NASDAQ: VTRS, Viatris or the Company ) announced today that the previously announced cash tender offers (the Any and All Tender...
Viatris Inc. (NASDAQ: VTRS) announced the expiration of its cash tender offers for outstanding senior notes from both Viatris and its subsidiary Mylan. A significant amount of senior notes were validly tendered before the expiration. The company is set to pay holders who participated for their tendered notes on September 16, 2024, pending the satisfaction of certain conditions. Meanwhile, Viatris plans to fund the purchases using cash reserves, thus illustrating its financial capability.
Read more →VTRSViatris Announces the Pricing Terms of Pending Any and All Cash Tender Offers Viatris Inc. (NASDAQ: VTRS, Viatris or the Company ) announced today the pricing terms of the previously announced cash tender offers (the Any...
Viatris Inc. has announced the pricing terms of its cash tender offers for outstanding senior notes due in 2025 from both Viatris and its subsidiary Mylan Inc. The offers are set to expire at 5:00 p.m. New York City time on September 10, 2024, unless extended or terminated. Total consideration amounts for the senior notes have been specified, and additional details regarding the yields and spreads are provided in their Offer to Purchase. This move aims to streamline the company's financial obligations.
Read more →VTRSViatris Announces Cash Tender Offers for Certain Outstanding Notes 1 PITTSBURGH
Viatris Inc. has announced cash tender offers for specific outstanding notes, primarily targeting the Viatris and Mylan senior notes due in 2025 and a maximum tender offer for senior notes due in 2026. The tender offers are set to expire on September 10, 2024, for Viatris and Mylan notes, and on October 2, 2024, for the Utah Acquisition notes. Holders must tender their notes prior to specified expiration dates to receive total consideration. This move reflects Viatris's strategy to manage its debt effectively.
Read more →VTRSViatris Presents Late Breaking Abstract on Cenerimod at the 26th Asia-Pacific League of Associations for Rheumatology Annual Congress Viatris Inc. (NASDAQ: VTRS), a global healthcare company, presented today the results of one of its Phase 2 studies* of cenerimod (ACT-333441). The...
Viatris Inc. presented findings from a Phase 2 study of cenerimod, which demonstrated safety and efficacy for the treatment of moderate to severe systemic lupus erythematosus (SLE) in Japanese patients. The study, accepted as a late-breaking abstract, indicated that both doses of cenerimod were well-tolerated, with significant improvements in disease activity noted. These results were found to be consistent with other global Phase 2 studies and contribute to the ongoing development of cenerimod as a potential therapeutic option for SLE.
Read more →VTRS▲ +6.5%on this news
Document Viatris Reports Second Quarter Financial Results for 2024 Strong Results Demonstrate Power of Company's Diversification, Execution and Growing Base Business Total Revenues of $3.8 Billion and Operational Revenue
Viatris Inc. reported strong financial results for Q2 2024, achieving total revenues of $3.8 billion and operational revenue growth of 2%. Despite a reported net loss of $326 million on a U.S. GAAP basis, adjusted EBITDA and EPS showed growth of 2% and 3%, respectively, on a divestiture-adjusted basis. The company also raised its full-year revenue projections for new product revenues following the completion of strategic divestitures, which they view as a turning point for future growth and shareholder returns.
Read more →VTRS▲ +6.5%on this news
Viatris Reports Second Quarter Financial Results for 2024 Strong Results Demonstrate Power of Company's Diversification, Execution and Growing Base Business Total Revenues of $3.8 Billion and Operational...
Viatris Inc. (NASDAQ: VTRS) announced robust financial results for the second quarter of 2024, featuring total revenues of $3.8 billion and strong growth in new product revenues. The company's efforts in diversifying its portfolio and completing divestitures are evident, as it recorded its fifth consecutive quarter of operational revenue growth. Despite some declines in U.S. GAAP net earnings and free cash flow, Viatris aims to expedite growth and shareholder returns through its established financial strengths and innovation focus.
Read more →VTRSViatris Announces Second Quarter 2024 Dividend Viatris Inc. (NASDAQ: VTRS) today announced that on August 5, 2024, its Board of Directors declared a quarterly dividend of $0.12 per share for each...
Viatris Inc. has announced a quarterly dividend of $0.12 per share, which will be payable on September 13, 2024. Shareholders of record as of August 23, 2024, will receive this dividend, highlighting the company's financial commitment to its investors. This announcement reflects Viatris's ongoing strategy to provide shareholder value and indicates a stable financial position. Moreover, Viatris continues to focus on empowering health globally through access to medicines.
Read more →VTRSViatris Brings to Completion All Previously Announced Divestitures With the Closing of its Over-the-Counter Business Divestiture Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it has closed the divestiture of its Over-the-Counter (OTC) business...
Viatris Inc. (NASDAQ: VTRS) has successfully completed the divestiture of its Over-the-Counter (OTC) business to Cooper Consumer Health, marking a significant milestone in its strategic plan. This closure is part of a series of divestitures intended to simplify operations and focus on higher-growth areas. The company retains rights to certain products while the move is expected to strengthen its financial position and enable strategic investments. Future updates will reflect financial guidance adjustments post-OTC business closure.
Read more →VTRSU.S. Department of Justice Informs Viatris That It No Longer Considers Mylan a Subject of Generic Drug Industry Antitrust Investigation Viatris Inc. (NASDAQ: VTRS) today announced that the Antitrust Division of the U.S. Department of Justice ( DOJ ) has advised that it no longer...
Viatris Inc. announced that the U.S. Department of Justice has concluded its antitrust investigation concerning Mylan and its former President, Rajiv Malik. The DOJ's Civil Division has also stated it does not plan any further actions regarding a civil investigative demand on generic drug pricing. This decision supports Viatris’ claims of no evidence of wrongdoing, allowing the company to move forward while defending against ongoing civil lawsuits.
Read more →VTRSViatris Named to TIME's World's Most Sustainable Companies 2024 List Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it has been named to the inaugural edition of TIME's World's Most...
Viatris Inc. (NASDAQ: VTRS) has been recognized as one of TIME's World's Most Sustainable Companies for 2024, showcasing its commitment to sustainability. The selection was based on over 20 performance indicators, with Viatris being one of the top 500 out of 5,000 evaluated companies. This recognition follows other accolades, including being named on USA TODAY's America's Climate Leaders list and 3BL's 100 Best Corporate Citizens. Viatris emphasizes the importance of sustainable access to healthcare and continues to work towards closing gaps in healthcare delivery globally.
Read more →VTRSViatris to Report Second Quarter 2024 Financial Results on August 8, 2024 Viatris Inc. (NASDAQ: VTRS) will report its second quarter 2024 financial results on Thursday, August 8, 2024, before the open of the U.S. financial...
Viatris Inc. is set to announce its financial results for the second quarter of 2024 on August 8, 2024, prior to the U.S. market open. The announcement will be followed by a webcast led by CEO Scott A. Smith and other executives at 8:30 a.m. ET, which will be accessible to both investors and the public. This initiative reflects Viatris's ongoing commitment to transparency and communication regarding its financial performance.
Read more →VTRSViatris to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the company will participate in the Goldman Sachs 45th Annual Global...
Viatris Inc. (NASDAQ: VTRS) has announced its participation in the Goldman Sachs 45th Annual Global Healthcare Conference, scheduled for June 11, 2024, in Miami Beach, Florida. The company will be represented by its Chief Executive Officer Scott A. Smith and other executives in a fireside chat at 9:20 a.m. ET. Interested investors can access a live webcast of the event, with an archived version available afterward. This engagement is part of Viatris' broader mission to provide access to healthcare globally.
Read more →VTRSViatris Appoints Rogerio Vivaldi Coelho, M.D., to Board of Directors Pittsburgh
Viatris Inc. has appointed Dr. Rogerio Vivaldi Coelho to its Board of Directors as part of ongoing board refreshment efforts. Dr. Vivaldi will serve on the newly reestablished Science and Technology Committee and is expected to contribute significantly to the company's growth strategy and innovative pipeline. With extensive experience in leading successful approvals of orphan products and a strong industry background, his addition aims to bolster the company's commitment to delivering high-quality medicines globally.
Read more →VTRSViatris to Participate in the Jeffries Global Healthcare Conference Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the company will participate in the Jeffries Global Healthcare Conference...
Viatris Inc. (NASDAQ: VTRS) has announced its participation in the upcoming Jeffries Global Healthcare Conference, scheduled for June 6, 2024, in New York. CEO Scott A. Smith along with other executives will represent the company during a scheduled fireside chat. The event will be accessible via a live webcast, with an archived version available afterward. Viatris aims to bridge the gap between generics and brand medicines, serving approximately 1 billion patients globally each year.
Read more →VTRSViatris Publishes 2023 Sustainability Report: Building Sustainable Access at Scale Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today published its 2023 Sustainability Report: Building Sustainable Access at Scale. The...
Viatris Inc. has published its 2023 Sustainability Report, detailing efforts to enhance global healthcare access and build healthier communities. The report emphasizes the company's commitment to supplying high-quality medicines to around 1 billion patients each year. Key highlights include the launch of the documentary 'Empathy in Africa,' which showcases Viatris' contributions to healthcare in South Africa, specifically through the Rhiza Babuyile Clinic. Viatris aims to set a model for sustainable healthcare practices while addressing the inequities in access to care.
Read more →VTRSViatris Reports Strong First Quarter 2024 Financial Results and Reaffirms 2024 Financial Guidance Ranges Reports Total Revenues of $3.66 Billion; U.S. GAAP Net Earnings of $113.9 Million; Adjusted EBITDA of $1.19 Billion; U.S. GAAP EPS of $0.09; Adjusted ...
Viatris announced robust financial results for Q1 2024, reporting total revenues of $3.66 billion and net earnings of $113.9 million. The company achieved operational revenue growth for the fourth consecutive quarter, bolstered by better-than-expected new product launches. Viatris reaffirmed its financial guidance for 2024, adjusting ranges primarily due to recent divestitures. Additionally, the company returned $393 million to shareholders, reflecting strong cash flow generation and a focus on capital allocation.
Read more →VTRSDocument Viatris Reports Strong First Quarter 2024 Financial Results and Reaffirms 2024 Financial Guidance Ranges Reports Total Revenues of $3.66 Billion U.S. GAAP Net Earnings of $113.9 Million Adjusted EBITDA of $1.19
Viatris Inc. reported strong financial results for the first quarter of 2024, with total revenues reaching $3.66 billion and net earnings of $113.9 million. The company reaffirmed its financial guidance for the year, adjusting ranges to reflect the impacts of recent divestitures and acquisitions. Notably, it marked its fourth consecutive quarter of growth in operational revenue. Additionally, Viatris returned $393 million to shareholders through dividends and stock repurchases during the quarter.
Read more →VTRSViatris to Participate in the BofA Securities 2024 Health Care Conference Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the company will participate in the BofA Securities 2024 Health Care...
Viatris Inc. (NASDAQ: VTRS) announced its participation in the BofA Securities 2024 Health Care Conference. The event is scheduled for May 14, 2024, at the Encore Hotel in Las Vegas, Nevada. Chief Financial Officer Doretta Mistras and Chief R&D Officer Philippe Martin will represent the company in a fireside chat during the conference. Interested individuals can attend via a live webcast, with an archived version available later.
Read more →VTRSViatris Expands its Wellbeing Program with the Launch of Unmind, a Leading Workplace Resource Focused on Mental Health Viatris Inc. (NASDAQ: VTRS), a global healthcare company, recently launched Unmind as part of its global wellbeing program, Elevate. Unmind is a...
Viatris Inc. has introduced Unmind, a workplace mental health resource, as a part of its Elevate wellbeing program, aimed at enhancing employee mental health. This initiative highlights the importance of mental wellbeing, especially in light of increased depression and anxiety rates following the Covid-19 pandemic. With Unmind, all Viatris colleagues and up to five family members can access tailored mental health support. The collaboration is a significant step towards fostering a culture that prioritizes mental health in the workplace.
Read more →VTRSViatris to Report First Quarter 2024 Financial Results on May 9, 2024 Viatris Inc. (NASDAQ: VTRS) will report its first quarter 2024 financial results on Thursday, May 9, 2024, before the open of the U.S. financial...
Viatris Inc. (NASDAQ: VTRS) will announce its first quarter 2024 financial results on May 9, 2024, prior to the opening of the U.S. markets. CEO Scott A. Smith and company executives will lead a webcast at 8:30 a.m. ET for discussion of the results. Interested parties can listen to the call via a dedicated webcast or by phone. A recording of the call will be accessible afterward.
Read more →VTRSViatris Appoints Corinne Le Goff as Chief Commercial Officer Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that Corinne Le Goff has joined the company as Chief Commercial Officer and ...
Viatris Inc. has appointed Corinne Le Goff as its new Chief Commercial Officer, effective immediately. With over 25 years of experience in the biotech and pharmaceutical industries, Le Goff has held leadership positions at various companies, including Moderna and Amgen. Viatris CEO Scott A. Smith expressed optimism about Le Goff's capability to enhance the company's growth. Le Goff is excited to join Viatris, which aims to improve patient care for one billion patients annually.
Read more →VTRSViatris Announces the Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution) 0.75% in the United States Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the U.S. commercial launch of RYZUMVI™ (phentolamine ophthalmic solution) 0....
Viatris Inc. has launched RYZUMVI™ (phentolamine ophthalmic solution) 0.75% in the U.S., becoming the only FDA-approved eye drop to reverse pharmacologically-induced mydriasis. Approved in September 2023, RYZUMVI aims to enhance patient adherence to dilated eye exams, which are crucial for detecting several serious eye conditions. Clinical trials demonstrated that RYZUMVI significantly outperformed placebo in returning pupils to baseline size after dilation, offering a quicker recovery for patients. However, users should be vigilant about possible adverse reactions and contraindications.
Read more →VTRSViatris Hosts R&D Event Focusing on its Collaboration with Idorsia, Phase 3 Assets Selatogrel and Cenerimod and Key Elements of its Pipeline At a meeting with the investment community today, Viatris Inc. (NASDAQ: VTRS), a global healthcare company, will outline how it is continuing to...
Viatris Inc. hosted an R&D event to discuss its evolving research strategy and collaboration with Idorsia, focusing on the Phase 3 assets selatogrel and cenerimod. CEO Scott A. Smith highlighted the company's confidence in future growth driven by a strong portfolio and financial flexibility. Selatogrel is aimed at treating Acute Myocardial Infarction and cenerimod addresses systemic lupus erythematosus. Both candidates have received Fast-Track designation from the FDA to expedite their development.
Read more →VTRS▼ -7.1%on this news
Viatris Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance Meets 2023 Guidance for Total Revenues, Adjusted EBITDA and Free Cash Flow[1] Reports 2023 Total Revenues of $15.4 Billion, U.S. GAAP Net Earnings of ...
Viatris Inc. has announced its financial results for the fourth quarter and full year of 2023, reporting total revenues of $15.4 billion and adjusted EBITDA of $5.1 billion, meeting its previously set guidance. The company has achieved operational revenue growth for three consecutive quarters and expects continued growth into 2024. Additionally, Viatris has added two promising Phase 3 assets through a partnership with Idorsia and has approved a significant increase in its share repurchase program. The board also declared a dividend of $0.48 per share for 2024, indicating a commitment to returning capital to shareholders.
Read more →VTRS▼ -7.1%on this news
Viatris and Idorsia Enter Into Significant Global Research and Development Collaboration Expands Viatris' Portfolio of Innovative Assets by Immediately Adding Two Phase 3 Assets, Selatogrel and Cenerimod, Both With Blockbuster Revenue...
Viatris Inc. and Idorsia Ltd have announced a significant global collaboration for research and development, granting Viatris exclusive rights to two Phase 3 assets: selatogrel and cenerimod. Selatogrel is a self-administered treatment aimed at patients with acute myocardial infarction, while cenerimod may provide a novel oral therapy for systemic lupus erythematosus. Viatris has emphasized its robust infrastructure to enhance the development and commercialization of these treatments, with no additional regulatory approvals needed to finalize the agreement. The collaboration aims to leverage both companies' strengths to expedite the clinical programs and potentially improve patient outcomes.
Read more →VTRS▼ -7.1%on this news
Document Viatris Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance Meets 2023 Guidance for Total Revenues, Adjusted EBITDA and Free Cash Flow 1 Reports 2023 Total Revenues o
Viatris announced its financial results for the fourth quarter and full year of 2023, achieving total revenues of $15.4 billion and continuing operational growth. The company added two Phase 3 assets with significant revenue potential and increased its share repurchase authorization to $2 billion. Viatris also maintained its dividend policy and declared a quarterly dividend of 12 cents per share. Looking ahead, the company provided its financial guidance for 2024, expecting continued growth and stability in its operations.
Read more →VTRSViatris to Announce Fourth Quarter and Full-Year 2023 Financial Results Viatris Inc. (NASDAQ: VTRS) will announce its fourth quarter and full-year 2023 financial results Wednesday, Feb. 28, 2024, before the open of the...
Viatris Inc. (NASDAQ: VTRS) is set to announce its fourth quarter and full-year financial results for 2023 on February 28, 2024, before the U.S. market opens. CEO Scott A. Smith and other executives will host a webcast at 8:30 a.m. ET to discuss the results. Investors can listen live through a dedicated webpage or by phone, with a replay available afterward. Viatris emphasizes its mission to improve global healthcare access through a diverse portfolio and established supply chains.
Read more →VTRSViatris to Participate in 42nd Annual J.P. Morgan Healthcare Conference Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the company will participate in the 42nd Annual J.P. Morgan Healthcare...
Viatris Inc. (NASDAQ: VTRS) will participate in the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024. Key executives, including the CEO, President, and CFO, will represent the company during the event, which features a presentation followed by a fireside chat. Investors can access a live webcast of the discussion, with an archived version available afterward. This engagement highlights Viatris' commitment to addressing global healthcare needs through innovative solutions.
Read more →VTRSRobert J. Coury Remarks at the 2023 Viatris Annual Meeting of Shareholders The End of One Era and The Beginning of Another Dear Fellow Shareholders, Over twenty years ago when I first joined our legacy company Mylan, we
During the 2023 Viatris Annual Meeting, Robert J. Coury reflected on the company's journey since its inception, highlighting the successful establishment of Viatris and its strategic plans for the future. He presented a clear vision for Phase 2, which focuses on growth and innovation over the next decade while maintaining strong financial health. Coury announced leadership transitions to ensure continued progress and expressed confidence in the company's ability to generate significant free cash flow for shareholder returns. Overall, Viatris aims to build on its strengths to make a meaningful impact in global healthcare.
Read more →VTRSViatris Continues its Preparations for Phase 2 of its Strategic Plan by Announcing the Appointment of Theodora Doretta Mistras as Chief Financial Officer, Effective
Viatris Inc. has announced the appointment of Doretta Doretta Mistras as Chief Financial Officer, effective March 1, 2024, as part of its preparations for Phase 2 of its strategic plan. Philippe Martin has also been appointed as Chief R&D Officer. The company expresses gratitude to outgoing CFO Sanjeev Narula for his efforts during Phase 1 and emphasizes the strong financial expertise Mistras brings, which is aimed at enhancing shareholder value and enabling future growth. The leadership changes reflect Viatris's commitment to advancing its position in the healthcare market.
Read more →VTRSViatris Shareholders Re-elect All Nominated Directors and Approve All Voting Matters at Annual Meeting of Shareholders Viatris Inc. (NASDAQ: VTRS), a global healthcare company, announced that at its 2023 Annual Meeting of Shareholders held today, shareholders voted to ...
At the 2023 Annual Meeting, Viatris shareholders re-elected all nominated directors and approved all voting matters. Melina Higgins was elected as the new Chair of the Board, succeeding Robert J. Coury. Higgins brings significant experience and is expected to guide the company through its next growth phase while continuing the strategic plan initiated by the Board. The CEO has expressed optimism about the company's future prospects and commitment to shareholder value.
Read more →VTRSViatris to Participate in the Jefferies London Healthcare Conference Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the company will participate in the Jefferies London Healthcare Conference...
Viatris Inc. (NASDAQ: VTRS) has announced its participation in the Jefferies London Healthcare Conference slated for November 15, 2023. Key executives, including CEO Scott A. Smith, will represent the company in a scheduled fireside chat. Interested investors can access a live webcast during the event, with an archived version available afterwards. This approach reflects Viatris’ commitment to communication and engagement with its stakeholders.
Read more →VTRSViatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) Viatris Inc. (NASDAQ: VTRS), a global healthcare company, and Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced positive results from the...
Viatris Inc. and Theravance Biopharma announced positive top-line results from a Phase III trial in China for YUPELRI® (revefenacin) aimed at treating chronic obstructive pulmonary disease (COPD). The study demonstrated significant improvements in lung function compared to placebo, with results comparable to prior U.S. studies, thus supporting a regulatory application in China expected around mid-2024. This advancement is particularly timely given the high prevalence of COPD in China, affecting nearly 100 million people.
Read more →VTRSViatris Reports Strong Financial and Operational Results for the Third Quarter 2023 and Reaffirms Full-Year 2023 Adjusted EBITDA and Free Cash Flow Guidance Ranges[1] Reports Total Revenues of $3.94 Billion; U.S. GAAP Net Earnings of $332 Million; Adjusted EBITDA of $1.36 Billion; U.S. GAAP Net Cash Provided by...
Viatris Inc. reported strong financial results for Q3 2023, with total revenues of $3.94 billion, highlighting a second consecutive quarter of operational revenue growth. The company anticipates new product revenues of $450 million to $550 million annually, supporting its growth strategy. However, total net sales showed a decline of 3% on a U.S. GAAP basis, and adjusted net earnings decreased by 10% compared to the previous year. Viatris remains on track to complete planned divestitures by mid-2024, although sales challenges persist in certain segments.
Read more →VTRSDocument Viatris Reports Strong Financial and Operational Results for the Third Quarter 2023 and Reaffirms Full-Year 2023 Adjusted EBITDA and Free Cash Flow Guidance Ranges 1 Reports Total Revenues of $3.94 Billion U.S.
Viatris Inc. reported strong third quarter financial results, with total revenues of $3.94 billion and an adjusted EBITDA of $1.36 billion. The company continues to see operational revenue growth year-over-year, marking the second consecutive quarter of this trend. However, overall net sales declined by 3% due to various factors, including foreign exchange impacts. Viatris remains focused on completing its divestitures by mid-2024 and announced a quarterly dividend to its shareholders.
Read more →VTRSViatris to Host Webinar: The Power of Partnership to Address Antimicrobial Resistance Viatris Inc. (NASDAQ: VTRS), a global healthcare company, announced today it is hosting The Power of Partnership to Address Antimicrobial Resistance...
Viatris Inc. (NASDAQ: VTRS) is set to host a webinar titled 'The Power of Partnership to Address Antimicrobial Resistance' on November 14, 2023. The event aims to highlight the growing threat of antimicrobial resistance (AMR) and its devastating implications for global health. Expert panelists, including leaders from Viatris and the AMR Industry Alliance, will discuss the importance of collaboration in combatting this pressing issue. Attendees can register for the free webinar to participate in this critical discussion about AMR.
Read more →VTRSViatris Named to Forbes' Annual List of the World's Best Employers for the Third Year in a Row Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it has been named to Forbes' list of World's Best Employers 2023....
Viatris Inc. (NASDAQ: VTRS) has been named to Forbes' list of the World's Best Employers for 2023, marking the third consecutive year it has received this recognition. The accolade reflects the commitment of its employees to the company's mission of promoting global health. Viatris' ranking was determined through a survey conducted by Statista, evaluating the recommendations and ratings provided by over 170,000 employees worldwide. The company boasts a diverse portfolio and aims to provide access to high-quality medicines across the globe.
Read more →VTRSRajiv Malik to retire as President of Viatris effective
Rajiv Malik will retire as President of Viatris effective April 1, 2024, after nearly 40 years in the pharmaceutical industry. He played a pivotal role in integrating the company’s legacy entities, Mylan and Upjohn, and will remain on the Board of Directors. Executives, including Robert J. Coury and Scott A. Smith, expressed deep appreciation for Malik's leadership and contributions to the company's mission of improving global health. Malik’s retirement has been framed positively, with a focus on the continuity of his expertise in the company’s operations.
Read more →VTRSViatris Named to 3BL's 100 Best Corporate Citizens of 2023 Ranking Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced it has been named to 3BL's annual 100 Best Corporate Citizens ranking,...
Viatris Inc. (NASDAQ: VTRS) has been recognized in 2023 as one of 3BL's 100 Best Corporate Citizens, highlighting its commitment to environmental, social, and governance (ESG) practices. This recognition reflects the company's transparency and performance across a range of ESG factors. Viatris emphasizes empowering global health and sustainable access to medicine. The company has also received various accolades for its corporate responsibility efforts in recent years.
Read more →VTRSViatris to Release Third Quarter 2023 Financial Results on November 7, 2023 Viatris Inc. (NASDAQ: VTRS) plans to release its third quarter 2023 financial results on Tuesday, November 7 after the close of the U.S. financial...
Viatris Inc. (NASDAQ: VTRS) has announced it will release its third quarter 2023 financial results on November 7, following the close of U.S. financial markets. The company will host a webcast at 5:00 p.m. ET that day, where its CEO, President, and CFO will discuss the results. This engagement reflects the company's commitment to transparency and investor interaction.
Read more →VTRSViatris Announces Agreements on Remaining Planned Divestitures; Upon Closing Would Achieve its Original Total Target of a Multiple Above 12x on 2022 Estimated Adjusted EBITDA Total Gross Proceeds From All Divestitures, I
Viatris Inc. has announced agreements for the divestiture of its Over-the-Counter (OTC) business and other non-core assets, marking significant progress in its strategic plan. The company expects to achieve a gross proceeds multiple above 12x on its 2022 estimated adjusted EBITDA, which is a key milestone for its financial goals. CEO Scott A. Smith expressed optimism about retaining certain valuable assets such as Viagra and Dymista. The planned transactions are anticipated to close by Q1 2024 and will involve significant organizational adjustments, including the potential conveyance of over 6,000 employees and multiple facilities.
Read more →VTRSViatris and Ocuphire Pharma Announce FDA Approval of RYZUMVl™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g., Tropicamide) Agents Viatris Inc. (NASDAQ: VTRS), a global healthcare company, and Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical...
Viatris Inc. and Ocuphire Pharma have received FDA approval for RYZUMVI (phentolamine ophthalmic solution) 0.75%. This treatment targets pharmacologically-induced mydriasis caused by adrenergic agonists or parasympatholytic agents. Expected to be available in the U.S. in the first half of 2024, the approval reflects the companies' commitment to improving eye care and patient access. Clinical trials demonstrated significant efficacy across various age groups, though common side effects were reported.
Read more →VTRSViatris Named to TIME's World's Best Companies 2023 List Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it has been named to TIME's World's Best Companies 2023 list. This...
Viatris Inc. (NASDAQ: VTRS) has been named to TIME's World's Best Companies 2023 list, an accolade recognizing companies making significant impacts globally. CEO Scott A. Smith highlighted the company's commitment to providing sustainable access to quality medicines. The recognition is a testament to the strong corporate culture and financial foundation established over the past three years. Viatris's achievements also include other accolades for climate leadership and employee satisfaction, reflecting its dedication to corporate social responsibility.
Read more →VTRSViatris Announces U.S. FDA Tentative Approval of a Paediatric Formulation of Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC), a Once-daily Treatment for Children Living with HIV Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced U.S. Food and Drug Administration (FDA) tentative approval for a New Drug...
Viatris has announced that the U.S. FDA has granted tentative approval for a pediatric formulation of abacavir/dolutegravir/lamivudine tablets for oral suspension, targeting the treatment of HIV-1 infection in children. This fixed-dose combination is recommended by the WHO as a first-line regimen and is aimed at enhancing treatment access for children in low- and middle-income countries. The approval supports Viatris' sustainability goals and addresses the significant treatment gap among pediatric HIV patients, especially in regions with limited healthcare resources.
Read more →VTRSDocument Viatris Reports Strong Financial and Operational Results for Second Quarter 2023 and Reaffirms Full-Year 2023 Guidance Ranges 1 Reports Total Revenues of $3.92 Billion U.S. GAAP Net Earnings of $264 Million Adju
Viatris Inc. reported impressive financial results for the second quarter of 2023, with total revenues reaching $3.92 billion and net earnings of $264 million. The company has reaffirmed its full-year guidance and highlighted its focus on a forthcoming growth phase beginning in 2024. Notably, Viatris aims to achieve approximately $500 million in new product revenues this year, supported by strengths in generics and key brands. However, the company also experienced a decline in net earnings and certain product sales, raising questions about future market performance.
Read more →VTRSViatris Reports Strong Financial and Operational Results for Second Quarter 2023 and Reaffirms Full-Year 2023 Guidance Ranges[1] Reports Total Revenues of $3.92 Billion; U.S. GAAP Net Earnings of $264 Million; Adjusted EBITDA of $1.31 Billion; U.S. GAAP Net Cash Provided by...
Viatris Inc. reported strong financial results for Q2 2023, achieving total revenues of $3.92 billion. The CEO emphasized a positive outlook for future growth, particularly as the company enters Phase 2 of its strategy in 2024. Significant achievements included the launch of Breyna, a generic version of Symbicort, contributing to their diverse product portfolio. However, the company faced a 16% decline in U.S. GAAP net earnings and a decrease in gross profit margins compared to the previous year.
Read more →VTRSViatris and Mapi Pharma Announce FDA Acceptance of New Drug Application Filing for GA Depot for the Treatment of Relapsing Forms of Multiple Sclerosis Viatris Inc. (NASDAQ: VTRS), a global healthcare company, and Mapi Pharma Ltd., a fully integrated, late-stage clinical development pharmaceutical...
Viatris and Mapi Pharma announced the FDA's acceptance of their New Drug Application for GA Depot, a long-acting glatiramer acetate developed for relapsing forms of multiple sclerosis. The application is supported by positive results from a Phase III clinical trial, which demonstrated a significant reduction in the annualized relapse rate. The FDA has assigned a PDUFA action date of March 8, 2024, leading the companies to express confidence that GA Depot could enhance patient compliance and experience through fewer injections.
Read more →VTRSViatris Announces Launch of Breyna™ (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the First FDA-Approved Generic Version of Symbicort® for People with Asthma and Chronic Obstructive Pulmonary Disease, in Partnership with Kindeva Viatris Inc. (NASDAQ: VTRS), a global healthcare company, and Kindeva Drug Delivery L.P. today announced the launch of Breyna™ (budesonide and...
Viatris Inc. has launched Breyna™, the first FDA-approved generic version of Symbicort, aimed at patients with asthma and chronic obstructive pulmonary disease (COPD). The launch underscores the companies' commitment to increasing patient access to complex generic medicines. Breyna will be available in multiple dosage strengths and a copay program is being implemented to support affordability. While the product offers a new treatment option, it also carries warnings regarding potential serious side effects and is not suitable for acute exacerbations.
Read more →VTRSViatris to Report Second Quarter 2023 Financial Results on August 7, 2023 Viatris Inc. (NASDAQ: VTRS) plans to report its second quarter 2023 financial results on Monday, August 7 before the open of the U.S. financial...
Viatris Inc. (NASDAQ: VTRS) has announced it will report its second quarter 2023 financial results on August 7, 2023, prior to the opening of U.S. financial markets. CEO Scott A. Smith, President Rajiv Malik, and CFO Sanjeev Narula will host a webcast at 8:30 a.m. ET to discuss the results. Investors and the public can access the webcast live or through a replay on the company's investor website.
Read more →VTRSViatris Named to USA Today's Inaugural List of America's Climate Leaders 2023 Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it has been named to USA Today's inaugural list of America's Climate...
Viatris Inc. has been named to USA Today's inaugural list of America's Climate Leaders 2023, recognizing its efforts in reducing greenhouse gas emissions intensity. To qualify, companies needed to show significant progress in lowering emissions and maintain transparency in reporting. Viatris has committed to a 42% reduction in Scope 1 and 2 emissions by 2030 and a 25% reduction in Scope 3 emissions. This acknowledgment underscores the company's dedication to sustainability and responsible operations globally.
Read more →VTRSRobert J. Coury to Transition from Executive Chairman of Viatris to Chairman Emeritus and Senior Strategic Advisor to the Board and Management at the End of the Year Coury will serve in this new role until the end of 202
Robert J. Coury will transition from Executive Chairman to Chairman Emeritus and Senior Strategic Advisor at Viatris by the end of 2023. This change follows Coury's significant role in achieving stability and success for the company since its formation in 2020. He will continue to provide guidance until the end of 2025, despite stepping down from his executive role. The board will announce a new independent chair after the 2023 annual meeting, scheduled for mid-December.
Read more →VTRSViatris Announces Appointment of Leo Groothuis to Company's Board of Directors Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that as part of its ongoing board refreshment efforts, Leo Groothuis has...
Viatris Inc. has announced the appointment of Leo Groothuis to its board of directors as part of its ongoing efforts to refresh the board. Groothuis takes over a vacancy left by the departure of Michael Goettler and brings substantial experience from his role as General Counsel of HAL Investments. His expertise in corporate governance and capital markets is expected to enhance Viatris' strategic direction and shareholder value.
Read more →VTRSViatris to Participate in Goldman Sachs 44th Annual Global Healthcare Conference Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the company will participate in the Goldman Sachs 44th Annual Global...
Viatris Inc. (NASDAQ: VTRS) has announced its participation in the Goldman Sachs 44th Annual Global Healthcare Conference scheduled for June 13, 2023, in Dana Point, CA. CEO Scott A. Smith, President Rajiv Malik, and CFO Sanjeev Narula will represent the company in a fireside chat during the event. Interested parties can access a live webcast of the discussion, which will also be archived for later viewing. This participation reflects Viatris' commitment to advancing healthcare globally.
Read more →VTRSViatris Publishes Sustainability Report Showcasing 2022 Progress on Building Sustainable Access to Medicine Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today published its 2022 Sustainability Report showcasing its commitment, impact and...
Viatris Inc. has released its 2022 Sustainability Report, highlighting its efforts to promote sustainable access to medicine. The report outlines the company's accomplishments in improving global health and supporting environmental initiatives, having supplied medicines to around 1 billion patients. Viatris is a signatory to the United Nations Global Compact and is dedicated to fostering equality in healthcare access and curbing climate change. The report reiterates the company's ongoing commitment to transparency in its sustainability practices.
Read more →VTRS▲ +5.8%on this news
Document Viatris Reports Strong Financial and Operational Results for First Quarter 2023 and Reaffirms Full-Year 2023 Guidance Ranges 1 Reports Total Revenues of $3.73 billion U.S. GAAP Net Earnings of $225 million Adjus
Viatris Inc. reported strong financial and operational results for Q1 2023, with total revenues of $3.73 billion and U.S. GAAP net earnings of $225 million. The company's confidence is reflected in the reaffirmation of its full-year guidance and a return of approximately $400 million to shareholders through dividends and share repurchases. However, total net sales saw a 2% decline compared to Q1 2022, and gross profit margins decreased, which raises concerns about future profitability amidst mixed performance in product categories.
Read more →VTRS▲ +5.8%on this news
Viatris Reports Strong Financial and Operational Results for First Quarter 2023 and Reaffirms Full-Year 2023 Guidance Ranges[1] Reports Total Revenues of $3.73 billion; U.S. GAAP Net Earnings of $225 million; Adjusted EBITDA of $1.34 billion; U.S. GAAP Net Cash Provided by...
Viatris Inc. has reported strong financial results for the first quarter of 2023, with total revenues reaching $3.73 billion, despite a decline in net earnings. The company is reaffirming its financial guidance for the full year while preparing for new product launches that may augment its market position. Strong cash flow was noted, with significant amounts aimed at debt reduction and shareholder returns. The management remains optimistic about the company’s strategic direction as it transitions to Phase 2 of its growth plan in 2024.
Read more →VTRSViatris and Mapi Pharma to Highlight Latest Results of Multiple Sclerosis Research at American Academy of Neurology 75th Annual Meeting Viatris Inc. (NASDAQ: VTRS), a global healthcare company, and Mapi Pharma today announced that recent data from ongoing studies of GA Depot 40 mg...
Viatris Inc. and Mapi Pharma announced that they will present new data from ongoing studies of GA Depot 40 mg at the American Academy of Neurology's 75th Annual Meeting. This data includes results from a pivotal Phase III clinical trial evaluating the efficacy and safety of GA Depot as a once-monthly injection for treating relapsing forms of multiple sclerosis. Viatris emphasizes its commitment to improving patient access and care for individuals with MS through innovative treatment options. The event provides an opportunity to share findings with the neurology community.
Read more →VTRSViatris auf der LinkedIn-Liste der Top-Unternehmen in Irland für 2023 aufgeführt Viatris Inc. (NASDAQ: VTRS), ein weltweit tätiges Gesundheitsunternehmen, hat bekannt gegeben, dass Viatris in Irland für sein Engagement, seinen...
Viatris Inc. (NASDAQ: VTRS) has been recognized in LinkedIn's Top Companies list for Ireland in 2023 due to its commitment to employee development and a supportive workplace culture. The list, which assesses companies based on various career growth metrics, highlights Viatris's strong emphasis on inclusivity and diversity. Aishling Goulden, Head of HR Ireland & Komárom, expressed enthusiasm for this recognition, stating it reflects the company's mission to bridge the gap in healthcare access globally. Viatris continues to position itself as a leading employer in the competitive Irish job market.
Read more →VTRSViatris nombrada en la lista de las mejores empresas de LinkedIn de 2023 en Irlanda Viatris Inc. (NASDAQ: VTRS) una empresa de atención sanitaria global, ha anunciado que Viatris en Irlanda ha sido incluida en la lista 2023 Top...
Viatris Inc. has been recognized in LinkedIn's 2023 Top Companies list for its commitment to creating a supportive work environment and promoting employee growth in Ireland. The ranking reflects the company's focus on inclusion, diversity, and professional development opportunities. Aishling Goulden, the HR director, expressed pride in this acknowledgment, emphasizing Viatris's unique position to provide quality medical solutions globally. This honor highlights Viatris as a leading employer in the competitive Irish job market.
Read more →VTRSViatris nommée au classement LinkedIn Top Companies 2023 en Irlande Viatris Inc. (NASDAQ: VTRS) une société mondiale de soins de santé, a annoncé que Viatris en Irlande a été nommée au classement LinkedIn Top...
Viatris Inc. (NASDAQ: VTRS) has been ranked in the LinkedIn Top Companies 2023 in Ireland for its commitment to providing a dynamic and supportive workplace that fosters professional development. This accolade highlights the company's focus on inclusion and diversity, as well as its dedication to helping employees achieve their full potential. Viatris is recognized for offering career advancement prospects and a collaborative environment, which strengthens its position as a notable employer in Ireland's competitive job market.
Read more →VTRSViatris Named in 2023 LinkedIn Top Companies List in Ireland Viatris Inc. (NASDAQ: VTRS) a globally healthcare company, has announced that Viatris in Ireland has been named to LinkedIn's 2023 Top Companies list ...
Viatris Inc. (NASDAQ: VTRS) has been recognized in LinkedIn's 2023 Top Companies list in Ireland, highlighting its commitment to employee growth and a positive workplace culture. The recognition is based on a variety of factors, including career progression opportunities and workplace inclusivity. Viatris aims to empower its employees and maintain high standards of diversity, equity, and inclusion as part of its core mission. The company's performance in these areas positions it as a standout employer in a competitive job market.
Read more →VTRSViatris to Report First Quarter 2023 Financial Results on May 8, 2023 Viatris Inc. (NASDAQ: VTRS) plans to report its first quarter 2023 financial results on Monday, May 8 before the open of the U.S. financial markets....
Viatris Inc. (NASDAQ: VTRS) is scheduled to release its financial results for the first quarter of 2023 on May 8 before U.S. markets open. The event will feature a live webcast led by CEO Scott Smith, President Rajiv Malik, and CFO Sanjeev Narula at 8:30 a.m. ET. Investors can access the webcast through multiple channels, ensuring broader participation and engagement. Viatris continues to emphasize its commitment to delivering access to healthcare solutions globally.
Read more →VTRSNCD Academy Launches New Health Equity and Social Determinants of Health Course Viatris Inc. (NASDAQ: VTRS), a global healthcare company, and the American College of Cardiology (ACC) today released the latest NCD Academy course,...
Viatris Inc. (NASDAQ: VTRS) and the American College of Cardiology have launched a new online course on Health Equity and Social Determinants of Health as part of the NCD Academy. This initiative coincides with World Health Day and focuses on addressing non-communicable diseases (NCDs) through education. The course aims to enhance healthcare professionals' awareness and skills related to health disparities, emphasizing equitable healthcare access. It reflects Viatris' commitment to improving global health outcomes through education and collaboration with leading organizations.
Read more →VTRSViatris Wins Summary Judgment in New York Securities Class Action Viatris Inc. (NASDAQ: VTRS) announced that the U.S. District Court for the Southern District of New York has dismissed all claims against the Company ...
Viatris Inc. announced that the U.S. District Court for the Southern District of New York dismissed all claims in a securities class action lawsuit against the company. The Court concluded that the plaintiffs' allegations lacked factual and legal grounds, affirming Viatris’ position on issues relating to EpiPen pricing and generic drug practices. The company stated its commitment to legal compliance and plans to continue defending itself against baseless claims.
Read more →VTRSDocument Viatris Reports Strong Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Financial Guidance Company Meets its 2022 Adjusted Guidance After Incorporating the Fourth Quarter Impact of the Biosi
Viatris Inc. reported robust financial results for Q4 and full year 2022, matching its adjusted revenue and EBITDA guidance. The company announced a dividend policy of $0.48 per share and completed share repurchases amounting to $250 million. While experiencing a decline in total net sales by 11% year-over-year, executives maintained a positive outlook for 2023 and reaffirmed their growth projections for 2024. The firm is also actively managing its debt and executing planned divestitures.
Read more →VTRSViatris Announces Appointment of Scott A. Smith as CEO Effective
Viatris Inc. has announced the appointment of Scott A. Smith as its new Chief Executive Officer effective April 1, 2023. Smith, a veteran healthcare executive with over 35 years of experience, will be responsible for executing the company's Phase 2 strategic plan, slated for 2024. Michael Goettler, the current CEO, will assist in the transition before departing from the position. The Board of Directors expressed optimism about Smith's capabilities and the company's strong financial positioning moving forward.
Read more →VTRSViatris Reports Strong Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Financial Guidance Company Meets its 2022 Adjusted Guidance After Incorporating the Fourth Quarter Impact of the Biosimilars Transaction and Acquired IPR&D 2023...
Viatris Inc. reported strong financial results for the fourth quarter and full year 2022, meeting its adjusted revenue guidance. The company has initiated a dividend policy of $0.48 per share and repurchased approximately 21.2 million shares as part of its commitment to returning capital to shareholders. While total net sales were down 9% from 2021, management expressed optimism about future growth. Financial guidance for 2023 indicates expectations for solid performance amidst ongoing challenges.
Read more →VTRSViatris to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023 Viatris Inc. (NASDAQ: VTRS) plans to report its fourth quarter and full year 2022 financial results on Monday, February 27 before the open of the U.S....
Viatris Inc. plans to release its fourth quarter and full year 2022 financial results on February 27, 2023, before the U.S. markets open. The company's executive team will participate in a webcast that day at 8:30 a.m. ET to discuss the results. Investors and the public can access the webcast live or through a replay on the Viatris website.
Read more →VTRSViatris Closes Acquisitions of Oyster Point Pharma and Famy Life Sciences, Establishing New Viatris Eye Care Division Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it has closed its acquisitions of Oyster Point Pharma and Famy Life...
Viatris Inc. has completed the acquisitions of Oyster Point Pharma and Famy Life Sciences, thereby forming a new Eye Care Division. This strategic move aims to leverage the companies' combined expertise to establish Viatris as a leader in global eye care. The acquisitions are projected to significantly enhance Viatris' product offerings and could generate at least $1 billion in sales by 2028. The former CEO of Oyster Point Pharma, Jeffrey Nau, has been appointed to lead the new division.
Read more →VTRSViatris Announces Appointments of Scott A. Smith and Elisha W. Finney to the Company s Board of Directors Directors Neil Dimick and Ian Read Retire PITTSBURGH
Viatris Announces Appointments of Scott A. Smith and Elisha W. Finney to the Company s Board of Directors Directors Neil Dimick and Ian Read Retire PITTSBURGH December 29, 2022 Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that Scott A. Smith and E
Read more →VTRSViatris Inc. to Participate in 41st Annual J.P. Morgan Healthcare Conference Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the company will participate in the 41st Annual J.P. Morgan Healthcare...
PITTSBURGH , Dec. 23, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS ), a global healthcare company, today announced the company will participate in the 41 st Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 11 , 2023. Representing Viatris will be
Read more →VTRSViatris Announces Approval of Emissions Reduction Targets by the Science Based Target initiative (SBTi) Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that its near-term science-based emissions reduction targets have been...
PITTSBURGH , Dec. 14, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS ), a global healthcare company, today announced that its near-term science-based emissions reduction targets have been approved by the Science Based Targets initiative (SBTi). SBTi is a global body enabling bus
Read more →VTRSViatris Announces Donations Totaling $1 Million to Provide Aid Supporting Access to Healthcare, Food Security and Water Stewardship Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced it is donating a total of $1 million to aid in supporting access to...
The contribution includes donations to four organizations: Direct Relief, World Central Kitchen, WaterAid and World Food Program USA PITTSBURGH , Dec. 14, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS ), a global healthcare company, today announced it is donating a total of $1
Read more →VTRSViatris Completes Biosimilars Transaction with Biocon Biologics Receives a $2 Billion Cash Payment and $1 Billion of Convertible Preferred Equity Representing a Stake of at Least 12.9% (on a Fully Diluted Basis) in Bioco
Viatris Completes Biosimilars Transaction with Biocon Biologics Receives a $2 Billion Cash Payment and $1 Billion of Convertible Preferred Equity Representing a Stake of at Least 12.9% (on a Fully Diluted Basis) in Biocon Marks the First in a Series of Expected Initiatives to R
Read more →VTRSViatris Named U.S. In-House Legal Team of the Year for Intellectual Property Litigation by LMG Life Sciences Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it has been named the winner in three categories at the 10th annual...
PITTSBURGH , Nov. 18, 2022 /PRNewswire/ -- Viatris Inc . (NASDAQ: VTRS ), a global healthcare company, today announced that it has been named the winner in three categories at the 10th annual LMG Life Sciences 2022 Americas Awards, highlighting companies, law firms and legal prac
Read more →VTRSViatris Wins Court Decision Invalidating AstraZeneca's Symbicort® Patent Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it and Kindeva Drug Delivery L.P. have won a significant court...
Viatris and Kindeva previously announced that Mylan Pharmaceuticals Inc., a Viatris subsidiary, received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Breyna™ (Budesonide and Formoterol Fumarate Dihydrate Inhalation
Read more →VTRS▲ +13.1%on this newsshared move
Document Viatris Reports Strong Third Quarter 2022 Results Reaffirms 2022 Guidance Ranges 1 Across Total Revenues, Adjusted EBITDA and Free Cash Flow Driven by Solid Operating Momentum Despite Foreign Exchange Headwinds
Viatris Reports Strong Third Quarter 2022 Results Reaffirms 2022 Guidance Ranges 1 Across Total Revenues, Adjusted EBITDA and Free Cash Flow Driven by Solid Operating Momentum Despite Foreign Exchange Headwinds and Absorbing Inflation Impact to Date Reports Total Revenues of $4
Read more →VTRS▲ +13.1%on this newsshared move
Viatris Announces Two Acquisitions to Create What it Expects to be a Leading Ophthalmology Franchise; Plans to Provide Strategic Update on its February 2022 Investor Event Expects Biocon Biologics Transaction to Close Sh
Viatris Announces Two Acquisitions to Create What it Expects to be a Leading Ophthalmology Franchise; Plans to Provide Strategic Update on its February 2022 Investor Event November 7, 2022 Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it intends
Read more →VTRS▲ +13.1%on this newsshared move
Viatris Reports Strong Third Quarter 2022 Results Reaffirms 2022 Guidance Ranges [1] Across Total Revenues, Adjusted EBITDA and Free Cash Flow; Driven by Solid Operating Momentum Despite Foreign...
[1] Viatris is not providing forward-looking guidance for U.S. GAAP net earnings (loss) or a quantitative reconciliation of its 2022 adjusted EBITDA guidance. U.S. GAAP net cash provided by operating activities for 2022 is estimated to be between $3.1 billion and $3.3 billion . P
Read more →VTRSViatris to Report Financial Results for the Third Quarter 2022 and Provide an Update on its February 28 Investor Event on November 7, 2022 Viatris Inc. (NASDAQ: VTRS) will announce financial results for the third quarter of 2022 on Monday, November 7, 2022. Executive Chairman Robert J....
PITTSBURGH , Oct. 24, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS ) will announce financial results for the third quarter of 2022 on Monday, November 7, 2022 . Executive Chairman Robert J. Coury , Chief Executive Officer Michael Goettler , President Rajiv Malik , and Chief Fi
Read more →VTRS▲ +7.3%on this news
Viatris Named to Forbes' Annual List of the World's Best Employers for the Second Year in a Row Viatris Inc. (NASDAQ: VTRS), a global pharmaceutical company, today announced that it has been named to Forbes' list of World's Best Employers 2022....
Company rises to the top 10% of the 800 global employers included on the list PITTSBURGH , Oct. 11, 2022 /PRNewswire/ -- Viatris Inc . (NASDAQ: VTRS ), a global pharmaceutical company, today announced that it has been named to Forbes' list of World's Best Employers 2022 . Viatri
Read more →VTRSViatris Inc. to Participate in BofA Global Research Global Healthcare Conference Viatris Inc. (NASDAQ: VTRS), a global pharmaceutical company, today announced the company will participate in the BofA Global Research Global...
PITTSBURGH , Sept. 6, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS ), a global pharmaceutical company, today announced the company will participate in the BofA Global Research Global Healthcare Conference in London on Thursday, September 15, 2022 . Chief Executive Officer Mich
Read more →VTRSDocument Viatris Reports Strong Second Quarter 2022 Results Reports Total Revenues of $4.12 Billion U.S. GAAP Net Earnings of $314 Million Adjusted EBITDA of $1.48 Billion U.S. GAAP Net Cash Provided by Operating Activit
Viatris Reports Strong Second Quarter 2022 Results Reports Total Revenues of $4.12 Billion U.S. GAAP Net Earnings of $314 Million Adjusted EBITDA of $1.48 Billion U.S. GAAP Net Cash Provided by Operating Activities of $803 Million and Free Cash Flow of $719 Million Strong First
Read more →VTRSViatris Reports Strong Second Quarter 2022 Results Reports Total Revenues of $4.12 Billion; U.S. GAAP Net Earnings of $314 Million; Adjusted EBITDA of $1.48 Billion; U.S. GAAP Net Cash Provided by...
[1] Viatris is not providing forward-looking guidance for U.S. GAAP net earnings (loss) or a quantitative reconciliation of its 2022 adjusted EBITDA guidance. U.S. GAAP net cash provided by operating activities for 2022 is estimated to be between $3.1 billion and $3.3 billion . P
Read more →VTRSViatris Inc. to Release Second Quarter 2022 Financial Results on August 8, 2022 Viatris Inc. (NASDAQ: VTRS) plans to release its second quarter 2022 financial results on Monday, August 8 before the open of the U.S. financial...
PITTSBURGH , July 1, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS ) plans to release its second quarter 2022 financial results on Monday, August 8 before the open of the U.S. financial markets. Chief Executive Officer Michael Goettler , President Rajiv Malik , and Chief Financ
Read more →VTRSViatris to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference Viatris Inc. (NASDAQ: VTRS), a global pharmaceutical company, today announced the company will participate in the Goldman Sachs 43rd Annual Global...
PITTSBURGH , May 20, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS ), a global pharmaceutical company, today announced the company will participate in the Goldman Sachs 43 rd Annual Global Healthcare Conference at the Terranea Resort in Rancho Palos Verdes, CA on Tuesday, June
Read more →VTRSViatris Publishes Sustainability Report Highlighting 2021 Progress, Achievements and Goals Viatris Inc. (NASDAQ: VTRS), a global pharmaceutical company, today published its 2021 Sustainability Report, outlining the company's 2021...
PITTSBURGH , May 16, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS ), a global pharmaceutical company, today published its 2021 Sustainability Report , outlining the company's 2021 achievements and progress across key areas including Access and Global Health, Employees, Environ
Read more →VTRS▲ +5.3%on this news
Viatris Reports Strong First-Quarter 2022 Results First-Quarter 2022 Results Reflect Strong Operational Start to the Year Total Revenues Were $4.19 billion U.S. GAAP Net Earnings Were $399.2 million...
PITTSBURGH , May 9, 2022 /PRNewswire/ -- First-Quarter 2022 Results Reflect Strong Operational Start to the Year Total Revenues Were $4.19 billion U.S. GAAP Net Earnings Were $399.2 million Adjusted EBITDA was $1.59 billion U.S. GAAP Net Cash Provided by Operating Activities was
Read more →VTRS▲ +5.3%on this news
Document Viatris Reports Strong First-Quarter 2022 Results First-Quarter 2022 Results Reflect Strong Operational Start to the Year Total Revenues Were $4.19 billion U.S. GAAP Net Earnings Were $399.2 million Adjusted EBI
Viatris Reports Strong First-Quarter 2022 Results First-Quarter 2022 Results Reflect Strong Operational Start to the Year Total Revenues Were $4.19 billion U.S. GAAP Net Earnings Were $399.2 million Adjusted EBITDA was $1.59 billion U.S. GAAP Net Cash Provided by Operating A
Read more →VTRSViatris Inc. to Release First Quarter 2022 Financial Results on May 9, 2022 Viatris Inc. (NASDAQ: VTRS) plans to release its first quarter 2022 financial results on Monday, May 9, before the open of the U.S. financial markets....
PITTSBURGH , April 8, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS ) plans to release its first quarter 2022 financial results on Monday, May 9 , before the open of the U.S. financial markets. Chief Executive Officer Michael Goettler , President Rajiv Malik , and Chief Financi
Read more →VTRSSesame Workshop and Viatris Launch New Emotional Health and Wellbeing Resources for Families Grappling with Effects of COVID-19 Sesame Workshop, the nonprofit behind Sesame Street, is launching new bilingual resources made possible by Viatris Inc. (NASDAQ: VTRS) to support the ...
New Videos and Resources Support the Social and Emotional Needs of Families Across Generations PITTSBURGH , March 30, 2022 /PRNewswire/ -- Sesame Workshop, the nonprofit behind Sesame Street , is launching new bilingual resources made possible by Viatris Inc. (NASDAQ: VTRS ) to
Read more →VTRSViatris Defeats Biogen's Attempt to Revive Tecfidera Patent Viatris Inc. (NASDAQ: VTRS) today announced that it is pleased with the decision by the United States Court of Appeals for the Federal Circuit...
About Viatris Viatris Inc. (NASDAQ: VTRS ) is a new kind of healthcare company, empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise
Read more →VTRSViatris Inc. Announces Receipt of the First FDA Approval for Generic Version of Symbicort® Inhalation Aerosol, Breyna™ (Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol), in Partnership with Kindeva Viatris Inc. (NASDAQ: VTRS) and Kindeva Drug Delivery L.P. today announced that, Mylan Pharmaceuticals Inc., a Viatris subsidiary, has received...
Approval continues track record of successful firsts in developing complex generic medicines to help increase patient access PITTSBURGH and ST. PAUL, Minn., March 16, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS ) and Kindeva Drug Delivery L.P. today announced that, Mylan Pha
Read more →VTRS▼ -7.8%on this news
Viatris to Participate in Upcoming Investor Conferences Viatris Inc. (NASDAQ: VTRS) today announced the company will participate in the following investor conferences: Chief Executive Officer Michael...
PITTSBURGH , March 1, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS ) today announced the company will participate in the following investor conferences: Interested parties can access live webcasts of the events at investor.viatris.com . Archived versions also will be availabl
Read more →VTRS▼ -24.3%on this newsshared move
Viatris Reports Strong Fourth Quarter and Full-Year 2021 Financial Results; Issues 2022 Financial Guidance; Completes Comprehensive Strategic Review; Unveils Plan to Reshape the Company for the Future; Announces Combination of its Biosimilars Portfolio with Biocon Biologics in Exchange for up to $3.335 Billion Representing an Attractive Multiple to Viatris of 16.5x the Company's Biosimilars 2022E Adjusted EBITDA(1), the First in a Series of Expected Initiatives Anticipated to Unlock up to an... Biocon Biologics Transaction Consists of Pre-tax Consideration of up to $3.335 billion, Including $2 billion in Upfront Cash, $1 billion of...
PITTSBURGH , Feb. 28, 2022 /PRNewswire/ -- Biocon Biologics Transaction Consists of Pre-tax Consideration of up to $3.335 billion , Including $2 billion in Upfront Cash, $1 billion of Convertible Preferred Equity Representing a Stake of at Least 12.9% in Biocon Biologics (on a F
Read more →VTRS▼ -24.3%on this newsshared move
Document Viatris Reports Strong Fourth Quarter and Full-Year 2021 Financial Results and Issues 2022 Financial Guidance Completes Comprehensive Strategic Review and Unveils Plan to Reshape the Company for the Future Annou
Viatris Reports Strong Fourth Quarter and Full-Year 2021 Financial Results and Issues 2022 Financial Guidance Completes Comprehensive Strategic Review and Unveils Plan to Reshape the Company for the Future Announces Combination of its Biosimilars Portfolio with Biocon Biologics
Read more →VTRSViatris to Host Virtual Investor Event and Report Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022 Viatris Inc. (NASDAQ: VTRS) will host its investor event the morning of Monday, February 28, 2022, beginning at 8:30 a.m. ET. During the event, Chief ...
PITTSBURGH , Feb. 4, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS ) will host its investor event the morning of Monday, February 28, 2022 , beginning at 8:30 a.m. ET . During the event, Chief Executive Officer Michael Goettler , President Rajiv Malik and Chief Financial Offic
Read more →VTRSViatris is First to Receive FDA Approval of Generic Restasis® (Cyclosporine Ophthalmic Emulsion 0.05%) to Treat Dry Eye Disease Viatris Inc. (NASDAQ: VTRS) today announced that its subsidiary, Mylan Pharmaceuticals Inc., has received approval from the U.S. Food and Drug...
PITTSBURGH , Feb. 3, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS ) today announced that its subsidiary, Mylan Pharmaceuticals Inc., has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Cyclosporine Ophthalm
Read more →VTRSViatris Announces 9% Dividend Increase, Fourth Consecutive Quarterly Dividend Viatris Inc. (NASDAQ: VTRS) today announced that on Tuesday, January 4, its Board of Directors approved a 9% increase in its quarterly dividend and...
PITTSBURGH , Jan. 6, 2022 /PRNewswire/ -- Viatris Inc . (NASDAQ: VTRS ) today announced that on Tuesday, January 4 , its Board of Directors approved a 9% increase in its quarterly dividend and declared a dividend for the first quarter of 2022 of 12 cents ($0.12) per share on outs
Read more →VTRSViatris Wins Court Decisions on Sanofi Appeals of Lantus® Patent Invalidations Viatris Inc. (NASDAQ: VTRS) announced that it is pleased with decisions issued today which affirm the U.S. Patent and Trademark Appeal Board's prior...
These affirmances reinforce the company's continuing efforts to break down barriers to patient access for important medicines such as Semglee® through its Global Healthcare Gateway ®. Viatris and Biocon Biologics Ltd. launched their interchangeable Semglee® products (insulin glar
Read more →VTRSViatris to Move its Investor Event Previously Scheduled for January 7 to no Later Than February 28 When the Company Expects to Report its Fourth Quarter 2021 Results Viatris Inc. (NASDAQ: VTRS) today announced that it will move its investor event previously scheduled for Friday, January 7, 2022 to no later than...
PITTSBURGH , Dec. 17, 2021 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS ) today announced that it will move its investor event previously scheduled for Friday, January 7, 2022 to no later than February 28, 2022 in conjunction with the release of its fourth quarter 2021 results. The
Read more →VTRSViatris Named by Newsweek as One of America's Most Responsible Companies Viatris Inc. (NASDAQ: VTRS), a new kind of global healthcare company, today announced that Newsweek has named the company to its list of America's...
PITTSBURGH , Dec. 6, 2021 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS ), a new kind of global healthcare company, today announced that Newsweek has named the company to its list of America's Most Responsible Companies 2022 . This award is presented by Newsweek and Statista Inc., t
Read more →VTRSViatris Wins Federal Circuit Court Appeal Upholding District Court Decision Invalidating Biogen's Tecfidera® Patent Viatris Inc. (NASDAQ: VTRS) today announced that the United States Court of Appeals for the Federal Circuit affirmed the June 2020 decision by the...
"We are pleased with the outcome of the Federal Circuit case, which reinforces our continued commitment to providing the multiple sclerosis community with access to more affordable treatment options," said Michael Goettler , Chief Executive Officer of Viatris. "Bringing a product
Read more →VTRSViatris to Participate in Evercore ISI 4th Annual HealthCONx Conference Viatris Inc. (NASDAQ: VTRS) today announced the company will take part in a virtual fireside chat at the Evercore ISI 4th Annual HealthCONx...
PITTSBURGH , Nov. 18, 2021 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS ) today announced the company will take part in a virtual fireside chat at the Evercore ISI 4th Annual HealthCONx Conference on Wednesday, December 1, 2021 . Chief Executive Officer Michael Goettler , President
Read more →VTRSViatris and Biocon Biologics Announce Launch of Interchangeable SEMGLEE® (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection Viatris Inc. (NASDAQ: VTRS) and Biocon Biologics Ltd. today announced the U.S. launch of interchangeable biosimilars SEMGLEE® (insulin glargine-yfgn) ...
PITTSBURGH and BENGALURU, India , Nov. 16, 2021 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS ) and Biocon Biologics Ltd. today announced the U.S. launch of interchangeable biosimilars SEMGLEE ® (insulin glargine-yfgn) injection, a branded product, and Insulin Glargine (insulin glar
Read more →VTRSViatris Donates $1 Million as Founding Champion to New Orleans-based SBP's Got Your Back fund in Support of Housing Solutions for Veterans in Disaster-Impacted Communities Viatris Inc. (NASDAQ: VTRS), a new kind of global healthcare company, today announced a $1 million donation that will have multi-year impact to SBP,...
PITTSBURGH and NEW ORLEANS , Nov. 11, 2021 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS ), a new kind of global healthcare company, today announced a $1 million donation that will have multi-year impact to SBP , a national U.S.-based not-for-profit organization dedicated to shrinki
Read more →VTRS▲ +6.9%on this newsshared move
Viatris Reports Strong Third Quarter Results, Raises 2021 Financial Guidance and Announces Virtual Investor Event on January 7, 2022 Reports Third Quarter 2021 Financial Results: Total Revenues of $4.54 billion; U.S. GAAP Net Earnings of $312 million; Adjusted EBITDA of $1.70...
PITTSBURGH , Nov. 8, 2021 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS ) today reported strong results for the third quarter of 2021, highlighted by robust cash flow generation. Viatris also announced that its Board of Directors declared a quarterly dividend of eleven cents ($0.1
Read more →VTRSViatris' First-Ever Interchangeable Insulin Biosimilar Preferred on Express Scripts' Largest Formulary Viatris Inc. (NASDAQ: VTRS) is proud to confirm that Express Scripts, a leading pharmacy benefit management organization, will list Viatris'...
PITTSBURGH , Oct. 20, 2021 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS ) is proud to confirm that Express Scripts, a leading pharmacy benefit management organization, will list Viatris' interchangeable biosimilar Semglee ® (insulin glargine-yfgn) injection as a preferred insulin b
Read more →VTRSViatris Inc. to Release Third Quarter 2021 Financial Results on Nov. 8, 2021 Viatris Inc. (NASDAQ: VTRS) plans to release its third quarter 2021 financial results on Monday, Nov. 8, before the open of the U.S. financial...
PITTSBURGH , Oct. 13, 2021 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS ) plans to release its third quarter 2021 financial results on Monday, Nov. 8 , before the open of the U.S. financial markets. Chief Executive Officer Michael Goettler, President Rajiv Malik and Chief Financial
Read more →VTRSViatris Named Fifth on Fortune's Change the World List Viatris Inc. (NASDAQ: VTRS), a new kind of global healthcare company, today announced that Fortune has named the company fifth out of 53 on its...
PITTSBURGH , Oct. 11, 2021 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS ), a new kind of global healthcare company, today announced that Fortune has named the company fifth out of 53 on its Change the World list . The annual ranking showcases companies that have had a positive soci
Read more →VTRSViatris Inc. to Participate in Citi's 16th Annual BioPharma Conference Viatris Inc. (NASDAQ: VTRS) today announced the company will take part in a virtual fireside chat at Citi's 16th Annual BioPharma Conference on...
PITTSBURGH , Aug. 30, 2021 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS ) today announced the company will take part in a virtual fireside chat at Citi's 16th Annual BioPharma Conference on Friday, September 10, 2021 . Chief Executive Officer Michael Goettler and President Rajiv Ma
Read more →VTRSViatris Inc. to Participate in BofA Global Healthcare Conference Viatris Inc. (NASDAQ: VTRS) today announced the company will take part in a virtual fireside chat at the BofA Global Healthcare Conference on...
PITTSBURGH , Aug. 30, 2021 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS ) today announced the company will take part in a virtual fireside chat at the BofA Global Healthcare Conference on Wednesday, September 15, 2021 . Chief Financial Officer Sanjeev Narula will answer questions a
Read more →VTRS▲ +6%on this news
Document Viatris Reports Strong Second Quarter Results Board of Directors Declares Quarterly Dividend of Eleven Cents ($0.11) per Share Company Raises 2021 Financial Guidance PITTSBURGH
Viatris Reports Strong Second Quarter Results Board of Directors Declares Quarterly Dividend of Eleven Cents ($0.11) per Share Company Raises 2021 Financial Guidance PITTSBURGH - August 9, 2021 Reports Second Quarter 2021 Financial Results - Total Revenues of $4.58 billion, U
Read more →VTRS▲ +6%on this news
Viatris Reports Strong Second Quarter Results Reports Second Quarter 2021 Financial Results - Total Revenues of $4.58 billion, U.S. GAAP Net Loss of $279 million, Adjusted EBITDA of $1.68...
PITTSBURGH , Aug. 9, 2021 /PRNewswire/ -- Reports Second Quarter 2021 Financial Results - Total Revenues of $4.58 billion , U.S. GAAP Net Loss of $279 million , Adjusted EBITDA of $1.68 billion , U.S. GAAP Net Cash Provided by Operating Activities of $559 million , Free Cash Flo
Read more →VTRSViatris Inc. and Biocon Biologics Receive Historic Approval for First Interchangeable Biosimilar Semglee® (insulin glargine-yfgn) injection for the Treatment of Diabetes Viatris Inc. (NASDAQ: VTRS) and Biocon Biologics Ltd. (a subsidiary of Biocon Ltd.) today announced that the U.S. Food and Drug Administration (FDA)...
PITTSBURGH and BENGALURU, India , July 28, 2021 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS ) and Biocon Biologics Ltd. (a subsidiary of Biocon Ltd.) today announced that the U.S. Food and Drug Administration (FDA) has approved Semglee ® (insulin glargine-yfgn) injection as the fi
Read more →VTRSMylan Wins Dismissal of Kansas EpiPen® Direct Purchaser Case Viatris (NASDAQ: VTRS) today announced that the U.S. District Court for the District of Kansas granted Mylan's motion to dismiss in a lawsuit brought ...
PITTSBURGH , July 27, 2021 /PRNewswire/ -- Viatris (NASDAQ: VTRS ) today announced that the U.S. District Court for the District of Kansas granted Mylan's motion to dismiss in a lawsuit brought against it and Pfizer by KPH Healthcare Services, Inc. (KPH) on behalf of an asserted
Read more →VTRSViatris Inc. to Release Second Quarter 2021 Financial Results on Aug. 9, 2021 Viatris Inc. (NASDAQ: VTRS) plans to release its second quarter 2021 financial results on Monday, Aug. 9, before the open of the U.S. financial...
PITTSBURGH , July 8, 2021 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS ) plans to release its second quarter 2021 financial results on Monday, Aug. 9 , before the open of the U.S. financial markets. Chief Executive Officer Michael Goettler, President Rajiv Malik, and Chief Financia
Read more →VTRSMylan Wins Significant Summary Judgment Rulings in Kansas EpiPen® Class Action Viatris (NASDAQ: VTRS) today announced that the U.S. District Court for the District of Kansas ruled, in substantial part, in Mylan's favor on the...
PITTSBURGH , June 23, 2021 /PRNewswire/ -- Viatris (NASDAQ: VTRS ) today announced that the U.S. District Court for the District of Kansas ruled, in substantial part, in Mylan's favor on the company's summary judgment motion in the class action related to EpiPen® Auto-Injector.
Read more →VTRSViatris firma un memorando de entendimiento con Defeat NCD Partnership en el Instituto de las Naciones Unidas para Formación Profesional e Investigaciones (UNITAR) Viatris Inc. (NASDAQ: VTRS) y Defeat NCD Partnership (DNCD) en el Instituto de las Naciones Unidas para Formación Profesional e Investigaciones...
GINEBRA y DUBÁI, Emiratos Árabes Unidos, 29 de mayo de 2021 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS ) y Defeat NCD Partnership (DNCD) en el Instituto de las Naciones Unidas para Formación Profesional e Investigaciones (UNITAR), firmaron hoy un memorando de entendimiento centra
Read more →VTRSViatris Inc. to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference Viatris Inc. (NASDAQ: VTRS) today announced the company will take part in a virtual fireside chat at the Goldman Sachs 42nd Annual Global Healthcare...
PITTSBURGH , May 25, 2021 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS ) today announced the company will take part in a virtual fireside chat at the Goldman Sachs 42 nd Annual Global Healthcare Conference on Thursday, June 10, 2021 . Chief Executive Officer Michael Goettler , Pres
Read more →VTRSViatris Inc. Reports Strong First Quarter 2021 Financial Results, Reaffirms 2021 Guidance and Announces Inaugural Quarterly Dividend Reports First Quarter 2021 Financial Results - Total Revenue of $4.4 billion, U.S. GAAP net loss of $1.0 billion, Adjusted EBITDA of $1.6 billion,...
PITTSBURGH , May 10, 2021 /PRNewswire/ -- Reports First Quarter 2021 Financial Results - Total Revenue of $4.4 billion , U.S. GAAP net loss of $1.0 billion , Adjusted EBITDA of $1.6 billion , U.S. GAAP net cash provided by operating activities of $849 million , Free cash flow of
Read more →VTRSDocument Viatris Inc. Reports Strong First Quarter 2021 Financial Results, Reaffirms 2021 Guidance and Announces Inaugural Quarterly Dividend PITTSBURGH
Viatris Inc. Reports Strong First Quarter 2021 Financial Results, Reaffirms 2021 Guidance and Announces Inaugural Quarterly Dividend PITTSBURGH - May 10, 2021 Reports First Quarter 2021 Financial Results - Total Revenue of $4.4 billion, U.S. GAAP net loss of $1.0 billion, Adjus
Read more →VTRSViatris Inc. Releases Inaugural Sustainability Report, Reinforcing its Commitment to Better Health and Better Communities Worldwide Viatris Inc. (NASDAQ: VTRS), a new kind of healthcare company formed in November 2020, today released its inaugural sustainability report,...
PITTSBURGH , May 6, 2021 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS ), a new kind of healthcare company formed in November 2020 , today released its inaugural sustainability report, reinforcing its strong foundation in corporate social responsibility and commitment to doing its p
Read more →VTRSViatris Inc. to Participate in the 2021 RBC Capital Markets Global Healthcare Conference Viatris Inc. (NASDAQ: VTRS) today announced the company will take part in a virtual fireside chat at the 2021 RBC Capital Markets Global Healthcare...
PITTSBURGH , April 30, 2021 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS ) today announced the company will take part in a virtual fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference on Tuesday, May 18, 2021 . Chief Executive Officer Michael Goettler and Chie
Read more →VTRSViatris Inc. et Atomo Diagnostics annoncent un accord avec Unitaid pour élargir l'accès à l'autotest de dépistage du VIH Viatris Inc. et Atomo Diagnostics Limited (ASX:AT1) (Atomo) ont annoncé aujourd'hui un accord pluriannuel avec l'agence de santé mondiale Unitaid...
Le coût du test sera réduit afin d'en améliorer l'accès et d'encourager la demande dans 135 pays dont les revenus sont faibles ou moyens. PITTSBURGH et SYDNEY , 30 avril 2021 /PRNewswire/ -- Viatris Inc. et Atomo Diagnostics Limited (ASX:AT1) (Atomo) ont annoncé aujourd'hui un a
Read more →VTRSViatris Inc. to Participate in BofA Securities 2021 Health Care Conference Viatris Inc. (NASDAQ: VTRS) today announced the company will take part in a virtual fireside chat at the BofA Securities 2021 Health Care Conference...
PITTSBURGH , April 29, 2021 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS ) today announced the company will take part in a virtual fireside chat at the BofA Securities 2021 Health Care Conference on Tuesday, May 11, 2021 . President Rajiv Malik and Chief Financial Officer Sanjeev N
Read more →VTRSUn año después de los confinamientos en todo el mundo por la COVID-19, un panel médico analiza el impacto de la pandemia en los pacientes con condiciones subyacentes y la necesidad de priorizar las enfermedades crónicas en el futuro El miércoles 21 de abril, entre las 8:00 a. m. y las 9:30 a. m. hora de verano del este, el Consejo Empresarial para el Entendimiento Internacional...
WASHINGTON , 20 de abril de 2021 /PRNewswire/ -- El miércoles 21 de abril, entre las 8:00 a. m. y las 9:30 a. m. hora de verano del este, el Consejo Empresarial para el Entendimiento Internacional (BCIU) y Viatris (NASDAQ: VTRS ) organizarán conjuntamente un diálogo virtual despu
Read more →VTRSViatris Inc. to Release First Quarter 2021 Financial Results on May 10, 2021 Viatris Inc. (NASDAQ: VTRS) plans to release its first quarter 2021 financial results on Monday, May 10, before the open of the U.S. financial...
PITTSBURGH , April 12, 2021 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS ) plans to release its first quarter 2021 financial results on Monday, May 10 , before the open of the U.S. financial markets. The company also will host a webcast at 10 a.m. ET on May 10 to discuss the result
Read more →VTRSViatris Inc. and Kindeva Drug Delivery Announce FDA Tentative Approval of the First Abbreviated New Drug Application Generic Version of Symbicort® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol Viatris Inc. (NASDAQ: VTRS) and Kindeva Drug Delivery L.P. today announced that the U.S. Food and Drug Administration (FDA) granted tentative...
PITTSBURGH and ST. PAUL, Minn. , March 8, 2021 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS ) and Kindeva Drug Delivery L.P. today announced that the U.S. Food and Drug Administration (FDA) granted tentative approval of budesonide/formoterol fumarate dihydrate products, the first g
Read more →VTRSViatris Inc. to Participate in Barclays Global Healthcare Conference Viatris Inc. (NASDAQ: VTRS) today announced the company will take part in a virtual fireside chat at the Barclays Global Healthcare Conference on...
PITTSBURGH , March 4, 2021 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS ) today announced the company will take part in a virtual fireside chat at the Barclays Global Healthcare Conference on Wednesday March 10, 2021 . CEO Michael Goettler , President Rajiv Malik and Chief Financia
Read more →VTRSViatris Inc. Hosts Inaugural Investor Day Outlining Unique and Differentiated Business Model, High-Quality Operational Platform, and Focus on CSR and Financial Commitments At a virtual meeting with the investment community today, Viatris Inc. (NASDAQ: VTRS) will outline how the company expects to lead as a new kind of...
PITTSBURGH , March 1, 2021 /PRNewswire/ -- At a virtual meeting with the investment community today, Viatris Inc. (NASDAQ: VTRS ) will outline how the company expects to lead as a new kind of healthcare company with a unique and differentiated business model, high-quality operati
Read more →VTRSto Upjohn's Current Report on Form 8-K filed on
VIATRIS February 22, 2021 Exhibit Forward Looking Statements This presentation contains "forward-looking statements." These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may in
Read more →VTRSViatris Inc. Announces 2021 Financial Guidance and Reaffirms Strategic and Financial Commitments Viatris Inc. (NASDAQ: VTRS) today announced its 2021 financial guidance and reaffirmed its commitment to rapid de-leveraging, to enhancing and...
PITTSBURGH , Feb. 22, 2021 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS ) today announced its 2021 financial guidance and reaffirmed its commitment to rapid de-leveraging, to enhancing and growing free cash flows, particularly following the phasing out of one-time and other stand u
Read more →VTRSViatris Inc. to Hold Conference Call on Monday, Feb. 22, 2021, to Discuss 2021 Financial Guidance Viatris Inc. (NASDAQ: VTRS) today announced that it will host a conference call at 8 a.m. ET on Monday, Feb. 22 to discuss 2021 financial guidance....
PITTSBURGH , Feb. 9, 2021 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS ) today announced that it will host a conference call at 8 a.m. ET on Monday, Feb. 22 to discuss 2021 financial guidance. The briefing can be accessed live by calling (855) 493-3607 or (346) 354-0950 for intern
Read more →VTRSMylan Wins Summary Judgment in EpiPen® Litigation Brought by Sanofi Viatris Inc. (NASDAQ: VTRS) today announced that the U.S. District Court for the District of Kansas entered summary judgment in Mylan's favor in the...
PITTSBURGH , Dec. 18, 2020 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS ) today announced that the U.S. District Court for the District of Kansas entered summary judgment in Mylan's favor in the lawsuit brought against it by Sanofi related to its EpiPen® products. Viatris is extre
Read more →VTRSViatris Inc. Recommends Caution on TRC Capital Corp.'s Attempt to Acquire Shares at a Significant Discount via Mini-Tender Offer Viatris Inc. (NASDAQ: VTRS) has been notified of an unsolicited mini-tender offer by TRC Capital Corporation ( TRC ) to purchase up to 6,000,000...
PITTSBURGH , Dec. 15, 2020 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS ) has been notified of an unsolicited "mini-tender" offer by TRC Capital Corporation ("TRC") to purchase up to 6,000,000 shares, or approximately 0.497 percent, of the outstanding common stock of Viatris at a p
Read more →VTRSViatris Inc. Announces Additional Details of Previously Disclosed Global Restructuring Initiative Viatris Inc. (NASDAQ: VTRS) today announced additional details of its previously disclosed multi-year global restructuring initiative. The...
PITTSBURGH , Dec. 11, 2020 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS ) today announced additional details of its previously disclosed multi-year global restructuring initiative. The restructuring initiative is part of the company's previously announced roadmap to maximize long-t
Read more →VTRSViatris Inc. to Present at the J.P. Morgan 39th Annual Healthcare Conference January 14, 2021 and Will Host its Inaugural Investor Day March 1, 2021 Viatris Inc. (NASDAQ: VTRS) will present at the J.P. Morgan 39th Annual Healthcare Conference on Thursday, January 14, 2021. Michael Goettler, chief...
PITTSBURGH , Dec. 10, 2020 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS ) will present at the J.P. Morgan 39 th Annual Healthcare Conference on Thursday, January 14, 2021 . Michael Goettler , chief executive officer, will make a formal presentation about the company at 7:30 a.m. ET
Read more →VTRSSesame Workshop and Viatris Inc. Launch Global Resources to Help Children and Caregivers Manage Social and Emotional Needs During Upcoming Holiday Season and Beyond Ahead of a holiday season that will look dramatically different this year for many children and families, Sesame Workshop and Viatris Inc. (NASDAQ:...
NEW YORK , Dec. 7, 2020 /PRNewswire/ -- Ahead of a holiday season that will look dramatically different this year for many children and families, Sesame Workshop and Viatris Inc. (NASDAQ: VTRS ) are launching new resources to support the social and emotional needs of families acr
Read more →VTRSViatris Inc. Announces FDA Tentative Approval of a Pediatric Formulation of Dolutegravir (DTG) Under PEPFAR Viatris Inc. (NASDAQ: VTRS), a new kind of healthcare company, today announced tentative approval from the U.S. Food and Drug Administration (FDA)...
PITTSBURGH , Nov. 23, 2020 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS ), a new kind of healthcare company, today announced tentative approval from the U.S. Food and Drug Administration (FDA) for a New Drug Application for pediatric dolutegravir tablets for oral suspension, 10 mg.
Read more →VTRSViatris Inc. Launches as a New Kind of Healthcare Company, Positioned to Meet the World's Evolving Healthcare Needs Viatris Inc. (NASDAQ: VTRS) launched today following the successful combination of Mylan N.V. and Pfizer's Upjohn business. By combining these two...
Combination of Mylan and Pfizer's Upjohn Business Focused on Access and Improved Patient Health PITTSBURGH , Nov. 16, 2020 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS ) launched today following the successful combination of Mylan N.V. and Pfizer's Upjohn business. By combining th
Read more →VTRSUpjohn (A Business Unit of Pfizer Inc.) Combined Financial Statements as of
(A Business Unit of Pfizer Combined Financial Statements as of December 31, 2019 and 2018 and for the Years Ended December 31, 2019, 2018 and 2017 and Report of Independent Registered Public Accounting Firm Index to Financial Statements Page Report of Independent Register
Read more →Competitive Position
How VTRS ranks across every disease it competes inCompetitive Position is a premium feature
See how VTRS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial